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The NLRP3 inflammasome is a critical mediator of inflammation and consists of the
sensor NOD-like receptor family, pyrin domain containing 3 (NLRP3), the adaptor
apoptotic speck protein containing a caspase recruitment domain (ASC), and the effector
caspase-1. Dysregulated or excessive activation of the NLRP3 inflammasome
contributes to pathogenesis of diverse inflammatory diseases such as Type 2 diabetes
and atherosclerosis. Therefore, the NLRP3 inflammasome is a promising therapeutic
target for treating these diseases. Extracellular vesicles (EVs) are membrane-enclosed tiny
particles released by almost any type of cells and they are involved in the intercellular
communication by transferring their cargos including RNAs, proteins, and lipids to target
cells. Based on their sizes, origins, and biological functions, EVs are mainly classified into
exosomes, microvesicles and apoptotic bodies. Recently, exosome-like nanoparticles
(ELNs) have been isolated from some edible plants, and their beneficial effects on diseases
have also been reported. Given that mushrooms have been utilized as medicines for long
time in some countries and they have anti-cancer, anti-inflammation and anti-microbial
properties, we isolated ELNs from six mushrooms and tested their effects on the NLRP3
inflammasome activation. Among these six mushroom-derived ELNs, shiitake-derived
ELNs (S-ELNs) significantly suppressed NLRP3 inflammasome activation and therefore
were chosen for further study. S-ELNs were nanoparticles that contained RNAs, proteins,

and lipids. RNA-labeled S-ELNs or lipid-labeled S-ELNs were taken up by macrophages
in a dose-dependent manner. S-ELNs had a broad inhibitory effect on the NLRP3
inflammasome activated by FFA, alum, nigericin, and ATP. S-ELNs inhibited assembly of
the NLRP3 inflammasome. Importantly, we further identified lipids in S-ELNs lipids as
active biomolecules that play an important role in suppressing NLRP3 inflammasome
activation. Taken together, our findings suggested that S-ELNs is a promising agent that
suppresses NLRP3 inflammasome activation.
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CHAPTER 1. LITERATURE REVIEW
Inflammation is important for eradication of pathogens and beneficial for the
wound and tissue healing (1,2). There are two types of inflammation: acute inflammation
and chronic inflammation (3). The clinical features of acute inflammation are pain, heat,
redness and swelling (4,5). At the cellular and molecular levels, acute inflammation is
characterized by increased permeability of the vascular, blood flow, leukocytic infiltration,
and the release of inflammatory mediators (3,6). When the pathogens or dangerous signals
are not eradicated completely, chronic inflammation occurs and lasts for weeks, months or
even years (1). Chronic inflammation is mainly characterized by the development of
immune responses at the infection site, which contributes to the pathogenesis of chronic
diseases, including cardiovascular diseases, type 2 diabetes and renal diseases (6,7). Both
acute and chronic inflammatory are involved in the recruitment of immune cells and the
accumulation of inflammatory mediators, but the severity of chronic inflammation is subtle
compared with acute inflammation (6).
In response to infection or cellular stress, the innate immune system plays an
important role in detecting and eliminating dangerous signals, including microorganisms
or endogenous damage (9,8). Pattern recognition receptors (PRRs), such as Toll-like
receptors (TLRs) and NOD-like receptors (NLRs), recognize these dangerous signals by
sensing pathogen-associated molecular patterns (PAMPs) and damage-associated
molecular patterns (DAMPs), leading to the recruitment of innate immune cells and the
upregulation of proinflammatory cytokines (8). Inflammasomes, a subgroup of PRRs, are
multiple protein complexes that are critically engaged in the immune responses to
eradicate microorganisms and tissue repair (9). Among the inflammasomes, the NLRP3
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inflammasome is most extensively and widely studied because it recognizes many
DAMPs and PAMPs, and thus engaged in the chronic inflammation in many diseases
(10).
The NLRP3 inflammasome consists of the sensor NOD-like receptor family,
pyrin domain containing 3 (NLRP3), the adaptor apoptotic speck protein containing a
caspase recruitment domain (ASC), and the effector caspase-1 (Casp1) (10,11). It can be
activated by various stimuli, including molecules introduced during both pathogen
infection and endogenous damage (10,11). Activation of the NLRP3 inflammasome
results in autocleavage of Casp1 to produce Casp1 p10 and p20, which cleaves prointerleukin (IL)-1β and pro-IL-18 into active interleukin-1β (IL-1β) and IL-18 (10-12).
IL-1β is one of the most important proinflammatory cytokines that plays a vital role in
inflammatory responses (12), and engaged in various chronic inflammatory diseases,
including type 2 diabetes and atherosclerosis (13,14).
Under normal physiological condition, activation of the NLRP3 inflammasome
contributes to the microorganism elimination and tissue repair (9). However,
dysregulated or excessive activation of the NLRP3 inflammasome promotes progress of
diverse diseases (10,11). Increasing evidence has suggested that the NLRP3
inflammasome is a promising therapeutic target in diverse chronic inflammatory diseases
(15). Nlrp3-/- obese mice have lower glucose levels in blood and higher insulin
sensitivity, compared with Nlrp3+/+ obese mice (16,17). The inhibitor MCC950 that
specifically targets NLRP3 inflammasome alleviated the severity of experimental
autoimmune encephalomyelitis (18).
Extracellular vesicles (EVs) are membrane-enclosed tiny particles released by
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almost any type of cells and they are involved in the intercellular communication by
transferring their cargos including RNAs, proteins, and lipids to target cells (19,20). EVs
are mainly classified into three different categories based on their sizes, origins, markers
or biological functions: exosomes (30-100 nm), microvesicles (50-2000 nm) and apoptotic
bodies (500-5000 nm) (21). Exosomes are released from endosomal membrane through
invagination. Exosomes are released from many mammal cells through exocytic fusion of
multivesicular bodies with cell surface and they have been isolated from urine, plasma,
saliva and milk (20, 25-28). Microvesicles are produced from plasma membrane through
budding (22). Apoptotic bodies are usually larger than exosomes and microvesicles. They
are produced during apoptosis progresses (21). However, the strict standard for EV’s
nomenclature or classification has not been well clarified and established. Importantly, EVs
play a significant role in both physiological and pathological processes (23). Therefore,
they begin to serve as biomarkers or therapeutic targets in many diseases (23). In the
physiological process, EVs secret from donor cells and deliver their cargos to recipient
cells, thereby maintaining homeostasis such as tissue repair and immune surveillance
(24,25). On the other hand, EVs contribute to the pathological process of some diseases
such as Alzheimer disease and cancer (26,27).
Recently, exosome-like nanoparticles (ELNs) have been isolated from some edible
plants, and their beneficial effects on diverse diseases have also been reported (28-30).
ELNs from plants share some similarity with mammal-derived exosomes: they are both
sphere nanoparticles carrying cargos of RNAs, proteins and lipids. The exosomes from
mammalian cells, mammalian tissues, or cow milk are often authenticated by immunoblot
analysis of exosome-specific surface markers (31-33), but such specific surface markers of
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ELNs from plants have not been established. Therefore, the nanoparticles isolated from
plants are usually called exosome-like nanoparticles (ELNs) (34,35).
Dietary exosomes or ELNs can be taken up by cells and subsequently have
biological effects on them (34,36-38). Dietary exosomes like milk exosomes were taken
up by mammalian cells through endocytosis (36). It was suggested that glycoproteins on
the surface of exosomes are essential for the uptake of milk exosomes (37). The membraneenclosed structure of dietary exosomes or ELNs provides protection for their cargos such
as RNAs and proteins from degradative condition of the gastrointestinal tract (39). One
study showed that RNA cargos from milk exosomes were distributed to brain and kidneys
in mice, which is distinctive from the distribution of the intact milk exosomes (40).
Depletion of dietary milk exosomes could affect cognitive ability in mice, suggesting the
important functions of milk exosomes in animals (38). Grape-derived ELNs were taken up
by mouse intestinal stem cells, and promoted their proliferation, and therefore protect mice
against DSS-induced colitis (30). All these findings suggest that dietary exosomes or ELNs
have biological functions in the consumers.
Mushrooms, which belong to Basidiomycetes and Ascomycetes, have been
considered as one of the most nutritional foods because they are enriched in carbohydrates,
proteins, unsaturated fatty acids, and vitamins (41). Moreover, some of mushrooms have
been widely used for the treatment of many diseases in certain countries because of their
medical properties including anti-inflammatory, anti-cancer, antioxidant, anti-microbial
and anti-diabetes properties (42-47). Increasing evidence has suggested that mushrooms
have therapeutic potential for the prevention or treatment of diseases including cancers,
diabetes and atherosclerosis (48-50). Mushrooms play an important role in inhibiting
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tumor growth, reducing blood glucose, enhancing immunity, and protecting against
infection (49,51-53). A variety of bioactive compounds, including polysaccharides,
flavonoids, phenolic compounds, terpenoids and lectins, have been identified in
mushrooms and they are suggested to account for the medical functions of mushrooms
(43).
The regulatory roles of diet in the NLRP3 inflammasome activity has been reported.
Saturated fatty acids (SFAs) including palmitate and stearate activate the NLRP3
inflammasome and thus induce the release of IL-1β (54). However, unsaturated fatty acids
(UFAs) including oleate linoleate, and omega-3 fatty acids suppress activation of the
NLRP3 inflammasome, therefore reducing IL-1β secretion (55,56). Like UFAs, a variety
of natural dietary compounds including polyphenols and flavonoids inhibit activation of
the NRLP3 inflammasome (57,58). Hence, these studies suggest an alternative strategy of
using natural dietary compounds or adjusting our dietary patterns for the treatment of
chronic inflammatory diseases. Here, the NLRP3 inflammasome, the mechanism of
NLRP3 inflammasome activation, inflammasome-related inflammatory diseases,
extracellular vesicles in disease, functions of dietary exosomes or ELNs, effects of dietary
molecules on activation of the NLRP3 inflammasome, and medical functions of
mushrooms are discussed.
1.1 NLRP3 inflammasome
NLRP3 is one member of the nucleotide-binding domain and leucine-rich repeat
containing gene family (NLR) family (59). NLR family members usually serve as sensors
for recognition of pathogens and other dangerous signals. There are 34 NLR family
members in mice and 22 NLR family members in humans (60). The NLRs contain a N-
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terminal effector region, a centrally located nucleotide-binding-and-oligomerization
(NOD) domain (or NACHT domains) and C-terminal leucine-rich repeats (LRRs) (60).
The N-terminal effector region mediates downstream interactions between proteins; The
centrally located NOD domain participates in oligomerization; The C-terminal LRRs are
involved in stimuli recognition (60). The NLRP3 inflammasome is a multiple protein
complex, which contains the sensor NLRP3, the adaptor ASC, and the effector caspase-1.
ASC participates in assembly of the NLRP3 inflammasome and contains caspase
recruitment domain (CARD) domain which is responsible for recruiting caspase-1 (61).
Upon activation of the NLRP3 inflammasome, ASC is recruited by NLRP3, and
subsequently forms specks in the perinuclear area of the cells. Therefore, ASC specks could
be used as an indicator of inflammasome assembly (62-64). ASC further recruits the
effector caspase-1 to form the NLRP3 inflammasome complex. Activation of the NLRP3
inflammasome causes the autocleavage of caspase-1 to produce the proteolytic active
caspase-1 p10 and p20, which cleaves pro-IL-1β and pro-IL18 into active IL-1β and IL18 (65,66) (Figure 1). In addition, active caspase-1 also induces pyroptosis, a specific
type of inflammatory cell death that release DAMPs (67). Both cytokine release and
pyroptosis are essential contributors to the inflammasome-mediated inflammatory
process.
1.2 Activation of the NLRP3 inflammasome
Activation of the NLRP3 inflammasome requires two signals (68). The first signal,
such as exogenous pathogens or endogenous molecules, induces Nlrp3 and Il1b gene
expression through toll-like receptor (TLR) / nuclear factor (NF)- κB pathway. The second
signal triggers the assembly of inflammasome and activation of caspase-1. The second
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signal could be PAMPs and DAMPs, such as adenosine triphosphate (ATP), pore-forming
toxins, and viral RNA (61) (Figure 1). Intracellular K+ efflux, reactive oxygen species
(ROS) production, lysosomal destabilization and rupture have been suggested as upstream
events of NLRP3 inflammasome activation (9,69).
1.2.1 Intracellular K+ efflux
The release of extracellular ATP triggered by cellular injury or necrosis stimulates
K+ efflux via the purinergic P2X7 receptor and thus activates the NLRP3 inflammasome
(70). The efflux of K+ induced by pore-forming toxin nigericin is necessary for activation
of the NLRP3 inflammasome (71). The low intracellular levels of K+ induced by ATP and
nigericin promote the release of IL-1β (72), while inhibition of K+ efflux suppresses the
release of IL-1β (73), which suggests the indispensable role of K+ efflux in ATP and
nigericin-mediated NLRP3 inflammasome activation. However, Intracellular K+
depletion alone is not sufficient for promoting IL-1β release (74). Furthermore,
particulate matter activates NLRP3 inflammasome by triggering the cell membrane
permeable to K+ (71). The release of IL-1β induced by imiquimod is not blocked by
manipulating K+ efflux. Thus, K+ efflux might not be an upstream event for NLRP3
inflammasome activation induced by imiquimod (75).
1.2.2 Reactive oxygen species (ROS) production
ROS production was suggested to serve as upstream of NLRP3 inflammasome
activation. ROS production induced by ATP stimulates the phosphatidylinositol 3kinase (PI3K) signaling pathway, resulting in activation of the NLRP3 inflammasome
and secretion of IL-1β (76). When ROS inhibitors N-acetyl-l-cysteine or (2R,4R)-4aminopyrrolidine-2,4-dicarboxylate were used, the secretion of IL-1β was decreased,
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implicating that ROS production is crucial for the NLRP3 inflammasome activation
(77). Furthermore, when RNA interference (RNAi) was used to downregulate ROS
detoxifying proteins, the secretion of IL-1β was increased (77). NAPDH oxidases
(NOXs) are involved in generation of ROS in cells (78). Interestingly, cells deficient in
NOX activity exhibited the normal amounts of IL-1β secretion, but treatment of ROS
scavengers in cells inhibited the secretion of IL-1β, suggesting ROS is required for
activation of the NLRP3 inflammasome, and NOXs are not the only source for ROS
production during inflammasome activation (79). Consistently, another ROS inhibitor
diphenyliodonium also inhibits NLRP3 inflammasome activation (80).
1.2.3 Lysosomal destabilization and rupture
Particulate matter, also called particle pollution, is solid and liquid droplets
suspended in air (81). A range of particulate matter (less than 1% of total particle mass)
such as silica, asbestos and alum activate the NLRP3 inflammasome (81-83). The
phagocytosis of particulate matter causes lysosomal swelling and rupture, release of
lysosomal contents into cytoplasm, and subsequent NRLP3 inflammasome activation
(82). The inhibition of phagocytosis impaired NRLP3 inflammasome activation in
response to particulate matter (82). The H+ ATPase inhibitor, which blocked lysosomal
acidification, attenuated NLRP3 inflammasome activation (82). The inhibition of
lysosomal protease also reduced activation of the NLRP3 inflammasome (82). These
studies indicated that lysosomal destabilization is required for the particulate matterinduced NLRP3 inflammasome activation.
1.3 Role of NLRP3 inflammasome activation in diseases
The NLRP3 inflammasome plays an important role in inflammatory responses
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and is incriminated in the pathogenesis of many metabolic diseases, including type 2
diabetes, atherosclerosis and liver disease.
1.3.1 Type 2 Diabetes
The NLRP3 inflammasome contributes to the progression of type 2 diabetes (84).
IL-1β, one downstream of NLRP3 inflammasome activation, induces the inflammation
in pancreatic islets, which leads to the destruction of β-cells, and therefore reduces
insulin production (85). Also, IL-1β leads to insulin resistance and affects the glucose
uptake (86). Increased macrophage infiltration has also been found in the pancreatic
islets of patients with type 2 diabetes (87). Knockout of NLRP3 in mice protected
pancreatic β-cells from damage and thus these mice had increased insulin levels in the
blood (17). The antidiabetic drug glyburide was shown to inhibit NLRP3 inflammasome
activation (88,89). TXNIP inhibitor, which inhibited the NLRP3 inflammasome
activation, enhanced glucose tolerance and insulin sensitivity in mice (16).
1.3.2 Atherosclerosis
Atherosclerosis has been considered as an inflammatory disease and is
characterized by the accumulation of lipids, cholesterol, and other substances in the
artery wall (90). Cholesterol metabolism is tightly linked with inflammation in
atherosclerosis (91). Cholesterol crystals are accumulated in atherosclerotic lesions and
trigger activation of the NLRP3 inflammasome and thus lead to IL-1β release from
macrophages in the lesions (92). The level of IL-1β is correlated with the severity of
atherosclerosis (92). IL-1β deficiency decreased the severity of atherosclerosis in
apolipoprotein E (ApoE) knockout mice (93). Similarly, knockdown of the Nlrp3 gene
in ApoE knockout mice showed lower levels of proinflammatory cytokines, less
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macrophage infiltration in the atherosclerotic lesions, and overall less severity of
atherosclerosis induced by hyperhomocysteinemia (94). Silencing the Nlrp3 gene or
using caspase-1 inhibitor blocked homocysterine-induced NLRP3 inflammasome
activation in macrophages (94). In addition, when RNAi was used to silence the sensor
NLRP3, cholesterol crystal-induced IL-1β secretion were decreased, suggesting the
important role of NLRP3 inflammasome in cholesterol crystal-induced inflammation
(95).
1.3.3 Liver disease
IL-1 β secreted by macrophages (Kupffer cells) in liver is key driven for alcoholinduced liver inflammation, steatosis, and damage, because IL-1 receptor antagonist
significantly attenuates this alcoholic hepatitis (96). The hepatocytes damaged by
alcohol release DAMPs, which activate the NLRP3 inflammasome in Kupffer cells (97).
When a mutant form of Nlrp3 gene resulting in a hyperactive NLRP3 was introduced in
mice, these knock-in mice show severe inflammation, fibrosis in liver and remarkable
hepatocyte pyroptotic cell death (98). Sulforaphane, which inhibits activation of the
NLRP3 inflammasome through AMP-activated protein kinase-autophagy axis,
attenuates hepatic steatosis in high fat diet-treated mice (99). Therefore, strategies that
inhibit IL1-β and NLRP3 inflammasome activation could have high therapeutic
potential to treat liver disease.
1.4 Extracellular vesicles
Extracellular vesicles (EVs) are phospholipid bilayer-enclosed tiny particles
released from eukaryotic and prokaryotic cells (19,20). Almost all the cell types, such
as T cell, dendritic cells, tumor cells, stem cells and endothelial cells, release EVs (23).
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EVs have been found in urine, saliva, blood plasma and breast milk (100-103). Based
on their sizes, origins, surface markers, and biological functions, EVs are mainly
classified

into

exosomes,

microvesicles

and

apoptotic

bodies

(20-22,104).

Ultracentrifugation, immunoaffinity and chromatography are typical approaches to
isolate EVs and subtypes of EVs can be isolated using different approaches (105). EVs
are recognized to transfer biological information between cells by carrying cargos of
RNAs, proteins and lipids (106). Importantly, EVs play a key role in both physiological
and pathological processes (19, 107).
1.4.1 Content of EVs
A variety of techniques have been used to characterize protein composition of
EVs, including mass spectrometry-based proteomics, western blotting, enzymatic
activity and serological reactivity (108,109). Some of proteins in EVs could serve as
biomarkers for diseases detection or targets of immunotherapies (110). CD63, CD9,
CD81, MHC I, MHC II, Gp96, Actinin-4, Tsg 101, heat-shock proteins 70 have been
identified as common surface biomarkers of EVs and some of them are specific surface
markers for some subgroups of EVs (111). In addition to the proteins, EVs are enriched
with RNAs, including mRNAs, miRNAs, rRNAs and tRNA fragments (112-114). Most
of the RNAs in EVs are very short and fragmented (115). RNAs delivered to the
recipient cells are actually functional (116). miRNAs in dendritic cell-derived exosomes
downregulate target genes in recipient dendritic cells (117). miR-155 encapsulated in
exosomes was delivered to cardiac fibroblasts and inhibited proliferation of these cells
(118). miR-135b in hypoxia-resistant multiple myeloma cell-derived exosomes
increased endothelial tube formation (46). Like proteins, miRNAs in EVs can be used
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as biomarkers for disease diagnosis or therapy because specific miRNAs could be
aberrantly enriched in EVs under certain pathological conditions (119,120). Exosomal
miR-1290 and miR-375 have been studied as promising biomarkers in diagnosis of
castration-resistant prostate cancer (121). EVs display a specific lipid composition and
organization (122). Usually glycosphingolipids, sphingomyelin, cholesterol and
phosphatidylserine are highly enriched in most EVs, indicating an important role of
these lipids in EVs biogenesis (123). These lipids contribute to the stability and
structural rigidity of EVs (124,125). Phosphatidylserine on the surface of exosomes is
thought to be an intercellular signaling, which can be recognized by Tim4 receptors on
the macrophages (126).
1.4.2 Physiological and pathological role of EVs
EVs are engaged in a variety of physiological and pathological processes by
mediating intercellular communication (127). Direct cell-cell communication is often
achieved through membrane surface molecules (128). In contract, EVs mediate
intercellular communication through their cargos of protein, RNAs, and lipids (106).
After EVs are taken up by recipient cells, their cargos are released and thus mediate the
functions of target cells (129). EVs are involved in stem cell maintenance, tissue repair,
immune surveillance, and blood coagulation (130). EVs from embryonic stem cells
deliver mRNA to recipient stem cells to increase their pluripotency (107). Microvesicles
released from mesenchymal stem cells inhibited apoptosis and promoted proliferation
of tubular epithelial cells, thereby protecting rats from acute kidney injury (131).
Exosomes released from B lymphocytes induce T cell responses (25). EVs released from
hepatocytes transferred RNAs to liver stellate-like cells and activate their proliferation
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(132). EVs released from neurons represent a novel way for inter-neuronal
communication, as specific neuron-derived EVs directly regulated signal transduction
and protein expression in target neurons cells (133).
Exosomes released from dendritic cells regulate the inflammatory response by
regulating inflammatory gene expression in recipient dendritic cells (134). Exosomes
derived from FasL-expressing dendritic cells inhibit inflammation in a murine arthritis
model (135). This study indicated that these specific exosomes may have the therapeutic
potential to treat arthritis (135). LPS-stimulated macrophage-derived exosomes have an
immunoprotective role, because an intraplantar injection of these exosomes reduced paw
thickness and thermal hypersensitivity in a mouse model of inflammatory pain (136).
Exosomes from body fluids of ovarian cancer patients have immunomodulatory
capacities because they trigger the gene expression of NF-κB- and STAT3-mediated
cytokines in monocytic precursor cells (137). Exosomes released from adipose-derived
stem cells increased insulin sensitivity, reduced weight and attenuated hepatic steatosis
in obese mice (138). Donor mouse-derived peripheral exosomes inhibited the
inflammation of the allograft heart in recipient mice by inducing Treg cells, which
potently suppress immune responses (139).
Because EVs transfer biological information between cells, it is possible that
EVs also transfer disease-driven factors between cells to spread diseases. EVs isolated
from parasite-infected host cells or plasma contain both host and parasite molecules,
disseminate the pathogens, and regulate the host immune systems (140). EVs participate
in the pathogenesis of various diseases, including osteoarthritis, atherosclerosis,
thromboembolism, chronic renal disease, pulmonary hypertension, periodontitis, gastric
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ulcers and bacterial infections (141). Tumor-derived EVs deliver causative molecules
such as microRNAs or oncogenes to recipient cells, resulting in the change of biological
functions, gene expression pattern, and overt tumorigenic conversion in recipient cells
(142). The levels of EVs are increased in atherosclerotic lesions and they may lead to
the progress of atherosclerosis (143). The level of plasma EVs is higher in patients with
cardiovascular diseases compared with healthy individuals. Therefore the circulating
EVs could be used as a prognostic marker for diagnosis of cardiovascular (144). EVs
cause extracellular matrix degradation and inflammation by carrying catabolic proteases,
antigens and miRNA, thus contributing to the pathophysiology of osteoarthritis and
rheumatoid arthritis (145). Given the fact that EVs mediate disease pathogenesis, the
potential use of EVs as diagnostic and therapeutic biomarkers has been explored in
various diseases. Developmental endothelial locus-1 protein in circulating EVs is a
promising biomarker, which could be potentially used to identify early-stage breast
cancer (146). Specific miRNA in salivary exosomes has the potential to be utilized as a
biomarker for diagnosis of salivary gland diseases such as Sjögren’s syndome (102).
1.5 Dietary exosomes or exosome-like nanoparticles (ELNs)
Dietary exosomes or ELNs have been demonstrated to participate in interspecies
communication (34). For example, grape-derived ELNs induced Lgr5 hi intestinal stem
cells and by doing so protected mice from DSS-induced colitis (30). Grapefruit-derived
ELNs attenuated DSS-induced colitis by inhibiting the production of IL-1β and Tumor
necrosis factor-α (TNF-α), suggesting their immune modulatory role in colitis (147). In
addition, grapefruit-derived ELNs have been utilized as a nano-vector to deliver
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therapeutic compounds to tumor sites (148). Compared with synthetic nanoparticles,
grapefruit-derived ELNs do not cause cytotoxic reactions (149).
Besides grape-derived and grapefruit-derived ELNs, milk exosomes gain
extensive interest. The exosome surface markers such as MHC, CD63, CD81 and CD86
are detectable in exosomes isolated from human breast milk, and these exosomes inhibit
the release of interleukin-2 (IL-2) and interferon- γ (IFN-γ), suggesting the immune
regulatory functions of these exosomes (103). Immune-related miRNAs are found in
breast milk exosomes and can be transferred to infants and thereby affect the
development of infant immune system (150). Bovine milk exosomes (BMEs) are taken
up by human and rate intestinal cells through endocytosis and glycoproteins on the
surfaces of exosome play important role in uptake of BMEs (151). The bioactivity of
BMEs has been demonstrated in vivo and in vitro. BMEs deliver miRNAs into
macrophages and therefore alter gene expression of inflammatory cytokine such as IL1, IL-6 and IL-10, and increase phagocytosis (152). Depletion of BMEs in the mouse
diet not only alters the gene expression pattern and the profiles of amino acid in skeletal
muscle of mice, but also alters their microbial communities in gut, suggesting that BMEs
facilitate the interspecies communication among cow milk, host, and microbiomes
(153,154). Compared with the distribution of intact BMEs, the distribution of specific
miRNA cargoes from BMEs has a distinct pattern in mice (155). Intact BMEs are mainly
accumulated in liver, spleen and brain, while their fluorescence-labeled microRNA
cargos distribute in intestinal mucosa, heart, liver, spleen and brain (155). BMEs
regulate lung inflammatory responses through promoting M1 macrophage polarization
and increasing the levels of IL-6 and TNF-α (156). BMEs were used for the delivery of
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chemotherapeutic/chemopreventive agents in mice and did not cause adverse immune
and inflammatory response (157). Therefore, BMEs have high potential to serve as a
drug delivery platform.
1.6 Effects of dietary molecules on activation of the NLRP3 inflammasome
1.6.1 Saturated fatty acids
Many foods are abundant in saturated fatty acids (SFAs), including fast foods,
meats and dairy products (158). Dietary SFAs trigger NLRP3 inflammasome activation
in adipocytes and macrophages via several possible mechanisms, including JNK
signaling pathways, toll-like receptor 2/4 (TLR 2/4) (159-162), or an AMPK-autophagyROS signaling pathway (163). It was also suggested that SFAs-induced NLRP3
inflammasome activation involves in Na, K-ATPase disruption and K+ efflux (164).
SFAs such as free fatty acids (FFAs) activate the NLRP3 inflammasome and result in
IL-1β secretion, which inhibits insulin signaling through serine-threonine kinase
phosphorylation and thereby leads to insulin resistance (163). A recent study shows that
the reduction of inter-endothelial tight junction proteins ZO1/2 and increased
permeability of endothelial monolayers were associated with FFAs-induced NLRP3
inflammasome activation because these impairments were reversed by NLRP3
inflammasome-related inhibitors such as HMGB1 inhibitor and lysosomal cathepsin B
inhibitor (165). Palmitate (PA), a long-chain SFA, activates NLRP3 inflammasome and
thus promotes inflammatory responses in cardiac fibroblasts (55). A new mechanism of
SFA-induced NLRP3 inflammasome activation was proposed recently. SFAs became
crystallized inside of macrophages, subsequently caused lysosomal dysfunction, and
therefore led to activation of the NLRP3 inflammasome (54).
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1.6.2 Unsaturated fatty acids
Unlike SFAs, unsaturated fatty acids (UFAs) inhibit NLRP3 inflammasome
activation in macrophages or monocytes (55). UFAs improve insulin resistance by
reducing NLRP3 inflammasome-dependent IL-1β secretion in high fat diet (HFD)induced obese mice (166). Fish oil enriches in omega-3 polyunsaturated fatty acids
(PUFAs), which are beneficial for human health. Interestingly, omega-3 PUFAs also
inhibit activation of the NLRP3 inflammasome and reduce transient expression of the
Il1b gene in peripheral blood mononuclear cells (167-169). In the traumatic brain injury
model, omega-3 PUFAs prevented mitochondrial localization of the sensor NLRP3 and
by doing so inhibited NLRP3 inflammasome activation and reduced IL-1β secretion
(170). Omega-3 PUFAs downregulated expression of inflammatory genes including
Nlrp3 and Il1b genes in adipocytes and monocytes/macrophages stimulated with LPS
plus INF-γ (171). IL-1β secretion and caspase-1 autocleavage were reduced in
macrophages and hepatocytes from dietary PUFAs-fed mice and it seems that dietary
PUFAs attenuated NLRP3 inflammasome activation through increasing autophagy
pathway (172). 17-oxo-DHA, a derivative of omega-3 fatty acids Docosahexaenoic acid
(DHA), inhibited NLRP3 inflammasome activation through suppressing mROS production
and ERK signaling in macrophages (173).
1.6.3 Other dietary components
Components extracted from various foods have anti-inflammatory properties.
Some of them inhibit activation of the NLRP3 inflammasome, though the underlying
mechanism is poorly understood. Epigallocatechin-3-gallate (EGCG) is a polyphenolic
component extracted from green tea. It has been shown that EGCG inhibited expression
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of Nlrp3 gene in mice with lupus nephritis (174). Another polyphenolic compound from
turmeric called curcumin inhibited caspase-1 autocleavage and IL-1β secretion upon
NLRP3 inflammasome activation, possibly by suppressing K+ efflux (175). Purple
sweet potato color (PSPC) is a flavonoid extracted from purple sweet potato. It inhibited
NF-kB nuclear translocation and NLRP3 inflammasome activation, and therefore
protected high-fat diet mice against hepatic inflammation (176). Fruits enriched in
procyanidins, such as grapes, have been reported to have inhibitory effects on
inflammatory response and inflammatory diseases (177,178). Later, Yang group
revealed that procyanidin blocked the transcriptional activity of activator protein-1
pathway, which led to the inhibition of ROS production, and subsequently suppressed
NLRP3 inflammasome activation in endothelial cells (57). Mangiferin isolated from
mangos inhibited activity of the transcription factor NF-kB, which regulates
transcription of many inflammatory genes including cytokines and chemokines (179).
Magniferin also inhibited NLRP3 inflammasome activity. As a result, Mangiferin
alleviated severity of some diseases including mastitis, traumatic brain injury and liver
injury (180-183). Resveratrol is enriched in fruits such as grapes, raspberries,
blueberries and mulberries (184). Resveratrol treatment helped to maintain
mitochondrial integrity, reduce the mROS production and therefore attenuate activation
of the NLRP3 inflammasome (185,186). Sulforaphane, a compound enriched in broccoli,
inhibited NLRP3 inflammasome activation and ameliorated Ischemia/reperfusion injury
and acute gout in animal models (187,188). It was demonstrated that Taiwanese green
propolis suppressed NLRP3 inflammasome activation and its bioactive compound called
propolin G likely mediated this inhibitory effect (189). In summary, these dietary
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components represent a novel and alternative strategy to inhibit activation of the NLRP3
inflammasome and thus curb or treat chronic low-grade inflammation in a variety of
diseases.
1.7 Medical functions of mushrooms
1.7.1 Anti-inflammatory property
Mushrooms have been reported to have anti-inflammatory functions. A
mushroom

called

Huaier

(Trametes

robiniophila

Murr.)

inhibited

NLRP3

inflammasome activation via the autophagy-lysosome degradation pathway, and
therefore attenuated symptoms of DSS-induced colitis (190). Glucans extracted from
Indian oyster (Pleurotus pulmonarius) also suppressed inflammation in DDS-induced
colitis, suggesting its potential role in the treatment of inflammatory bowel disease (191).
Ergosterol peroxide (a bioactive compound found in hen of the woods (Grifola
frondosa)), cauliflower mushroom (Sparassis crispa) and lingzhi mushroom
(Ganoderma lucidum), suppressed cytokine production by inhibiting mitogen-activated
protein kinases (MAPKs) signaling pathways or NF-κB signaling in macrophages (192194). Oyster mushroom (Pleurotus ostreatus) also showed anti-inflammatory function
because it suppressed TNF-α and IL 6 secretion both in vitro and in vivo (195). Addition
of portobello (Agaricus bisporus) and shiitake mushrooms (Lentinula edodes) in the diet
protected Ldlr-/- mice from high-fat diet-induced atherosclerosis (50).
1.7.2 Anti-cancer property
The anti-cancer property of mushrooms has been widely studied. A protein FVE
isolated from Enoki mushroom (Flammulina velutipes) and grifolin isolated from Sheep
Polypore mushroom (Albatrellus confluens) and white button mushroom (Agaricus
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bisporus) inhibited tumor growth, indicating that these mushrooms contain anti-tumor
agents (51,196,197). In most cases, mushrooms induce apoptosis of cancer cells. For
example, Chaga mushroom (Inonotus obliquus), lection isolated from Kurokawa
mushroom (Boletopsis leucomelas), and grifolin isolated from Sheep Polypore
mushroom (Albatrellus confluens) are all capable of inducing apoptosis of cancer cells
(197-199). Some studies have demonstrated that some of the mushrooms or their extracts,
such as willow bracket (phellinus igniarius) and polysaccharide lentinan from shiitake
mushroom (Lentinus edodes) caused cell cycle arrest at G0/G1 phase and prevented
tumor cell proliferation (200,201). White button mushroom (Agaricus bisporus)
inhibited the proliferation of both prostate cancer cells and breast cancer cells (51,202).
Song gen mushroom (Phellinus linteus) caused either cell-cycle arrest or apoptosis in
lung cancer cells depending the dosage used, suggesting it has an anti-cancer effect (203).
Ergosterol peroxide isolated from Chaga mushroom (Inonotus obliquus) inhibited
proliferation of colon cancer cells in vitro and tumor growth in mice (204).
1.7.3 Other properties
Besides anti-inflammatory and anti-cancer properties, mushrooms also show
other beneficial effects such as enhancement of immunity, antioxidant function, and
anti-microbial function (204-206). Mushrooms enhance immunity through stimulating
natural killer cell or increasing IFN γ and TNFα secretion (207). Consumption of dried
shiitake mushroom (Lentinus edodes) enhanced immunity in humans by promoting
proliferation of gamma delta T (γδ-T) cells and natural killer T (NK-T) cells and
increasing secretory immunoglobulin A in saliva (208). Lectin isolated from mushroom
Fomitella fraxinea has an immunomodulatory function. It increased major
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histocompatibility complex (MHC)-restricted antigen presentation and protected
chicken from coccidiosis (52,209). Oyster mushroom (Pleurotus ostreatus) extracts
protected rats from CCl 4-induced liver injury by decreasing the levels of liver-related
enzymes, including glutamic oxaloacetic transaminase, alkaline phosphatase and
glutamic pyruvate transaminase, and improved antioxidant activity of liver by increasing
antioxidant activity-related enzymes, such as catalase, glutathione peroxidase and
superoxide dismutase (210). Extracts (using ethanol) from crab-of-the-woods mushroom
(Laetiporus sulphureus), extracts (using water, methanol, acetone, and ethyl acetate)
from Enoki mushroom (Flammulina velutipes), white and brown shimeji variants
(Hypsizygus tesselatus) inhibited the growth of bacteria. These findings suggest that
these mushrooms contain antimicrobial agents, which could be potentially used for the
treatment of infection (46,211). Extracts (using water) from Almond mushroom
(Agaricus blazei Murill) protected mice against streptococcus pneumoniae infection
(53).
1.8 Conclusion
The NLRP3 inflammasome is a multiprotein complex that consists of the sensor
NLRP3, the adaptor ASC, and the effector caspase-1. Both endogenous DAMPs or
exogenous PAMPs can trigger NLRP3 inflammasome activation, thereby leading to
caspase-1 autocleavage and subsequent IL-1β secretion. Several models have been
proposed to explain how NLRP3 inflammasome activation is triggered. Intracellular K+
efflux, ROS production, lysosomal destabilization and rupture were indicated as the
upstream events of NLRP3 inflammasome activation. Dysregulated activation of the
NLRP3 inflammasome is involved in a variety of chronic diseases, such as type 2 diabetes,
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atherosclerosis and liver disease. EVs are phospholipid bilayer-enclosed tiny particles
released from eukaryotic and prokaryotic cells. They play an important role in
intercellular communication and even interspecies communication by delivering and
releasing cargos such as microRNAs in the target cells. Exosomes, a subtype of EVs,
are nanoparticles that contain lipids, RNAs, and proteins. Dietary exosomes or exosomelike nanoparticles (ELNs) are taken up by consumers, distributed in different tissues,
and have bioactive functions in animal models. Mushrooms have showed a range of
medical benefits to human health and therefore their bioactive components represent
promising candidates for the treatment of diseases. Therefore, in our studies, we aimed
to evaluate the effects of ELNs extracted from mushrooms on NLRP3 inflammasome
activity.
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CHAPTER 2. EXPERIMENTS AND RESULTS
2.1 Introduction
The NLRP3 inflammasome is a multiprotein complex composed of NLRP3, ASC
and caspase-1 (10,11). A variety of exogenous PAMPs or endogenous DAMPs stimulate
the NLRP3 inflammasome, leading to caspase-1 autocleavage and IL-1β and IL18
secretion (65). Activation of the NLRP3 inflammasome requires two signals: the first
signal stimulates expression of the Nlrp3 and Il1b genes; the second signal causes the
assembly of inflammasome complex, which activates the autocleavage of caspase-1 to
produce caspase-1 p10 and p20, and then cleave pro-IL-1β and pro-IL18 to generate active
IL-1β and IL 18 (65). IL-1β is a major cause of acute and chronic inflammation and thus
involved in the pathological processes of various inflammatory diseases (212). Therefore,
activation of the NLRP3 inflammasome contributes to the pathogenesis of these diseases.
Emerging evidence demonstrates that inhibition of the NLRP3 inflammasome suppresses
the secretion of IL-1β, and therefore improves the conditions of chronic inflammatory
diseases, including diabetics, Alzheimer’s disease and gout (213-215). In short, the NLRP3
inflammasome is suggested to be a promising therapeutic target for treatment of NLRP3
inflammasome-related diseases.
Exosomes are biolayer membrane-enclosed nanoparticles released from cells (20).
They participate in intercellular communication and even interspecies communication by
delivering and releasing their cargos of RNAs, proteins and lipids to target cells, thereby
regulating the bioactivity of target cells, including gene expression and functions (106).
Dietary exosomes or exosome-like nanoparticles (ELNs) have been obtained from diet
sources. A variety of dietary ELNs have been identified from edible plants such as ginger,
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carrots, grapefruit and grapes (34). In particular, dietary ELNs have therapeutic potential
for the treatment of diseases (30). Mushrooms have been utilized as medicines in certain
countries because of their anti-inflammatory, anti-cancer, antioxidant and anti-microbial
properties (42-47). We are highly interested in mushrooms due to their medical properties.
To the best of our knowledge, mushroom-derived ELNs have never been studied and the
effects of mushroom-derived ELNs on NLRP3 inflammasome activation has never been
evaluated.
In this study, shitake mushroom-derived ELNs (S-ELNs) were isolated and
characterized for the first time. We discovered the inhibitory effects of S-ELNs on NLRP3
inflammasome activation in macrophages. Furthermore, we identified that lipids in SELNs as active biomolecules that suppressed NLRP3 inflammasome activation.
Collectively, S-ELNs represent a promising agent that blocks NLRP3 inflammasome
activation.
2.2 Central Hypothesis, Purpose, and Specific Aims
A. Purpose of the Study
The purpose of the study is to investigate the effects of S-ELNs on the NLRP3
inflammasome activation in bone marrow-derived macrophages (BMDM) and identify
active biomolecules in S-ELNs with anti-inflammasome functions.
B. Central Hypothesis
S-ELNs inhibit NLRP3 inflammasome activation in macrophages.
C. Specific Aims
Specific Aim 1: Evaluate the effects of S-ELNs on NLRP3 inflammasome activation.
Specific Aim 2: Identify which category of cargos (RNAs, proteins and lipids) is the active
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biomolecules that inhibit the NLRP3 inflammasome in macrophages.
2.3 Materials and Methods
2.3.1 Preparation of S-ELNs
Mushrooms were washed with water and gently dried using tissues. After washing,
mushrooms were weighted and cut into small pieces. The mushroom pieces were put in
cold phosphate buffered saline (PBS) and homogenized in a kitchen blender for 15 seconds.
The juice was collected and centrifuged at 500g, 10 minutes 4 ℃ and then at 2000g, 20
minutes, 4 ℃, respectively. The juice was then collected and ultracentrifuged at 10,000g,
30 minutes, 4 ℃ and at 100,000g, 2 h, 4 ℃, respectively. The pelleted ELNs were
resuspended in 2 ml PBS and passed through a 0.45 m filter and then 0.2 m filter. The
concentration of ELNs was measured using the Nanosight NS300 machine (Malvern
Panalytical).
2.3.2 RNA depletion of S-ELNs
0.2 µl RNase (10 ng/ml) was added to 200 µl S-ELNs (3.55*1012 /ml). The solution
underwent bath sonication for 90 minutes at room temperature using a bath sonication
machine (Branson CPX5800H). After sonication, the solution was incubated at 37 ℃ water
bath for another 1 h.
2.3.3 Liposome preparation
Lipids in S-ELNs were extracted based on the Folch method (30). 1000 µl S-ELNs
(1.12*1012 /ml) were added to 3800 µl mixture of CHCl3 (1267 µl) : MeOH (2533 µl) at a
1:2 ratio (v/v) and vortex. An aliquot (1267 µl) of CHCl3 was added to the mixture. The
mixture was vortexed and stirred vigorously for 1 h. After stirring, 1267 µl molecular water
was added to the mixture. The mixture was vortexed and stirred vigorously for another 1
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h. The mixture was centrifuged at 2,000 g for 10 minutes at room temperature, and then
organic phase containing lipids was collected. The organic phase was dried under nitrogen
gas (0.2-0.5 psi) at 60 ℃. Dried lipids were suspended in 200 µl molecular water, and
subsequently sonicated for 5 minutes. 200 µl buffer (40 mM HEPES, 308 mM NaCL, Ph
7.4) was added and sonicated for another 5 minutes to obtain liposomes. The liposomes
were used immediately or stored at – 80 ℃.
2.3.4 Scanning electron microscopy (SEM)
S-ELNs were purified using sucrose gradient methods. 1000 µl crude S-ELNs were
added on top of sucrose gradient with density of 2M, 1.8M, 1.6M, 1.4M, 1.2M, 1M, 0.8M,
0.6M, 0.4M, 0.2M and then were ultracentrifuged at 100,000g, 12 h, 4 ℃. The layer
contains S-ELNs was collected and fixed with glutaraldehyde (final concentration 2.5%,
EMS#16320) for 30 minutes at room temperature. Subsequently, S-ENLs were fixed with
tannic acid (final concentration 1%, EMS#21700) for 30 minutes at room temperature.
After fixation, S-ELNs were loaded on the Nucleopore track-etched membrane (100 nm
pore size, Whatman), dried overnight, and sputter-coated using a Desk Vsputter (Denton
Vacuum InC). S-ELNs were visualized using scanning electron microscope (Hitachi S4700
FE).
2.3.5 Agarose gel, SDS-PAGE gel and Thin-layer Chromatography (TLC) analysis
Total RNAs were extracted from S-ELNs using commercial miRNeasy mini kit
(Qiagen). 700 µl QIAzol lysis reagent was added to S-ELN pellets. The RNAs were eluted
in 30 µl RNase-free molecular biology grade water (Corning). 400 ng RNAs were loaded
into 2% agarose gels to separate. Proteins extracted from S-ELNs were separated using
SDS-PAGE gels (Novex) and gels were stained using Coomassie Brilliant Blue. Lipids
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were extracted from S-ELNs using the Folch method mentioned above. The lipids were
separated on the thin-layer chromatography (TLC) plate (Millipore Sigma) using a solvent
system (chloroform : methanol : acetic acid at a ratio of 190:9:1, v/v/v) and visualized using
CuSO4 phosphric acid solution.
2.3.6 Macrophage cell culture and ELNs treatment
Mouse bone marrow-derived macrophages (BMDMs) were cultured using the bone
marrow cells from the femurs and tibias of C57BL/6 mice. The bone marrow cells stored
at -80 ℃ were thawed and cultured in growth media (61% RPMI 1640 media (Corning),
1% sodium pyruvate (Corning), 1% L-glutamine (Corning), 1% penicillin/streptomycin
(Corning), 1% HEPES (Corning), 25% L929 media and 10% fetal bovine serum (FBS,
Atlanta Biologicals)). Cells were incubated at 37 ℃ in 5% CO2 for 6-8 days until a uniform
monolayer of macrophages was established. Macrophages were split and seeded into a 12well plate with growth media overnight. The culture media were changed to plating media
(76% RPMI 1640 media (Corning), 1% sodium pyruvate (Corning), 1% L-glutamine
(Corning), 1% penicillin/streptomycin (Corning), 1% HEPES (Corning), 10 % L929 media
and 10% precleared-fetal bovine serum (FBS, Atlanta Biologicals)). 4 h later, S-ELNs were
added to cells. After 16 h S-ELN incubation, Lipopolysaccharide (LPS (10 ng/ml),
InvivoGen, tlrl-peklps) was added to cells and incubated for 3 h. Free fatty acid sodium
palmitate (FFA) (Sigma) was added to cells and incubated for another 12 h. The culture
medium was collected and centrifuged at 300 g, 5 minutes, 4℃ to remove cells and big
cell debris. The precleared culture medium was used to measure IL-1β release using ELISA
kit (eBioscience). The cell lysates were collected using Sodium Dodecyl Sulfate (SDS)
lysis buffer and subject to western blot to measure capase-1 autocleavage. Macrophages
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were also stimulated using Alum (Thermo Scientific), nigericin (Enzo Life Sci) or ATP
(Sigma) to activate the NLRP3 inflammasome.
2.3.7 ELISA and western blot
The level of IL-1β in the culture medium was measured using ELISA kit
(eBioscience). Proteins in cell lysates were separated using 4-12% SDS-PAGE gels
(Novex) and transferred into polyvinylidene difluoride (PVDF) membrane (0.45 µm, GE
Healthcare). Primary antibodies against tubulin, caspase-1 p10, pro-IL-1β, ASC, NLRP3
and Nek7 were used to incubate with membrane overnight. The secondary antibodies
including anti-rabbit-HRP, anti-mouse-HRP or anti-goat-HRP (Cell Signaling) were used
to detect the levels of proteins. Tubulin antibody was purchased from Santa Cruz
Biotechnology. Primary antibodies against NLRP3, ASC, caspase-1 p10 were purchased
from Adipogen. Primary antibody against Nek7 was purchased from Abcam. Anti-pro-IL1β antibody was purchased from R&D systems.
2.3.8 Uptake studies of S-ELNs
RNAs in S-ELNs were labeled using ExoGlowTM-RNA EV labeling kit (SBI
System Biosciences). 8.3 µl S-ELNs (1.83 *1012 /ml) were added to incubation buffer to
make a 50 µl solution. 3 µl ExoGlow RNA probe was added to the mixture and then the
mixture was incubated at 37 ℃ 1 h in dark. The mixture was added into 35 ml PBS and
ultracentrifuged at 100,000g, 2 h to remove free probes. The pellet of RNA-labeled S-ELNs
was suspended in 2 ml PBS. Lipids in S-ELNs were labeled using DiI dye (Thermo Fisher
Scientific) as per manufacturer’s protocol. After labeling, the mixture was added into 35
ml PBS and ultracentrifuged at 100,000g, 2 h to remove free DiI dye. The pellet of lipidlabeled S-ELNs was suspended in 2 ml PBS.
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Glass coverslips were pre-plated in a 24-well plate, and then macrophages were
seeded and cultured using growth media overnight. 4 h before S-ELNs were added to cells,
the culture medium was changed to plating medium. RNA-labeled or lipid-labeled S-ELNs
were added to macrophages. After 16 h incubation, macrophages were washed with PBS
for 3 times and fixed with 4% paraformaldehyde (Sigma) on ice for 20 minutes. After 20
minutes, macrophages were washed with PBS for 3 times. Nucleus was subsequently
stained using DAPI (Fisher Scientific). The uptake of fluorescence-labeled S-ELNs by
macrophages was evaluated using a confocal fluorescence microscope (Nikon A1R).
2.3.9 ASC speck detection
Glass coverslips were pre-plated in a 24-well plate, and then macrophages were
seeded and cultured using growth media overnight. The culture medium was changed to
plating media. 4 h later, S-ELNs were added to cells. After 16 h incubation, macrophages
were incubated with LPS (10 ng/ml) for 3 h, followed by incubation of caspase-1 inhibitor
VX765 (10 µM) for 0.5 h. Finally macrophages were stimulated with FFA for 12 h. After
12 h incubation, macrophages were washed with PBS for 3 times and fixed with 4%
paraformaldehyde (Sigma) on ice for 20 minutes. After 20 minutes, macrophages were
washed with PBS for 3 times. Rabbit anti-ASC antibody (Adipogen) was used to incubate
with macrophages overnight at 4 ℃. Secondary antibody anti-rabbit Alexa Fluor 594
(Invitrogen) was used. Nucleus were stained using DAPI (Fisher Scientific).
Immunofluorescence was detected using a confocal microscope (Nikon A1R).
2.3.10 RNA extraction and real time quantitative polymerase chain reaction (qPCR)
Macrophages were treated with S-ELNs for 16 h, incubated with LPS for 3 h, and
then activated with FFA for 12 h or ATP for 0.5 h. mRNAs were extracted from
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macrophages using RNA bee (Tel-Test) and then the concentration of mRNA was
measured. 1 µg mRNAs were used for cDNA synthesis using High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems). Quantitative polymerase chain reaction
(qPCR) was performed to assess expression of the genes including Nlrp3, Caspase1,
Pycard and Il1b using a real time qPCR machine (Bio-Rad). All genes were normalized to
a hypoxanthine guanine phosphoribosyl transferase (Hprt) gene. Primers of these genes
were designed in advance and ordered from Integrated DNA Technologies.
2.3.11 Statistical analysis
Comparisons of treatment group with control group were analyzed using two-tailed
t-test. P values were calculated: * P < 0.05, ** P < 0.01. Both * and ** were consided as
significant.
2.4 Results
2.4.1 S-ELNs strongly inhibited caspase-1 autocleavage and IL-1β secretion upon
NLRP3 inflammasome activation
Activation of the NLRP3 inflammasome leads to autocleavage of caspase-1 to
produce the enzymatic active caspase-11 p10 and p20, which process pro-IL1β and proIL18 to produce active IL-1β and IL18. Very often, caspase-1 autocleavage and IL-1β
secretion are used as indicators of NLRP3 inflammasome activation (65). To screen the
effects of different mushroom-derived ELNs on activation of the NLRP3 inflammasome,
six mushrooms were chosen to extract ELNs: White beach mushroom (White buna
shimeji), Brown beach mushroom (Brown buna shimeji), White common mushroom
(White agaricus bisporus), Brown common mushroom (Brown agaricus bisporus), King
mushroom (Pleurotus eryngii) and Shiitake mushroom (Lentinus edodes). Macrophages
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were treated with mushroom-derived ELNs for 16 h. Mushroom-derived ELNs-primed
macrophages were treated with LPS for 3 h and then were activated with FFA for 12 h.
Caspase-1 autocleavage and IL-1β secretion were measured using western blot and ELISA,
respectively. Among six mushroom-derived ELNs we tested, shiitake-derived ELNs (SELNs) strongly inhibited both caspase-1 autocleavage and IL-1β secretion in a dosedependent manner (Figure 2F). In contrast with S-ELNs, white beach-derived ELNs and
brown beach-derived ELNs had mild effects on caspase-1 autocleavage and IL-1β secretion
(Figure 2A, 2B). Although king-derived ELNs mildly inhibited IL-1β secretion at high
dose, it increased IL-1β at low dose and had no effects on caspase-1 autocleavage (Figure
2C). White common-derived ELNs and brown common-derived ELNs suppressed IL-1β
secretion, but they slightly increased caspase-1 production (Figure 2D, 2E). These results
suggested that ELNs from shiitake mushroom were the only mushroom-derived ELNs that
strongly inhibited caspase-1 autocleavage and IL-1β secretion upon NLRP3 inflammasome
activation. Therefore, S-ELNs were chosen for further studies.
2.4.2 Characterization of S-ELNs
The size and morphology of S-ELNs were first characterized using Nanosight
NS300 instrument and scanning electron microscope (SEM). Nanosight NS300
measurement showed that the size of S-ELNs was distributed from 80 nm to 300 nm in
diameter and most of them were accumulated at 115 nm in diameter (Figure 3A).
Consistently, we further confirmed that S-ELNs had different sizes under SEM (Figure
3B). S-ELNs were intact and round under SEM (Figure 3B), suggesting S-ELNs had
similar shape and size as those of mammalian exosomes (35).
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The cargos of S-ELNs were characterized by running RNA gel, protein gel, and
TLC plate. Based on RNA electrophoresis result, the size of RNA in S-ELNs is less than
50 nucleotides (nt) (Figure 3C). After adding RNase to RNA samples, the band was not
detected (Figure 3C), indicating that the nucleic acids we extracted were RNAs. The
proteins of S-ELNs were separated using SDS-PAGE gels. The results showed that three
main bands were visualized after Coomassie Brilliant Blue staining. Their sizes were
around 50 KDa, 30 KDa and 13 KDa, respectively (Figure 3D). The TLC plate results
showed that lipids in S-ELNs were separated into three bands, and the majority of lipids in
S-ELNs was accumulated on the top of the TLC plate (Figure 3E). These results
demonstrated that the ELNs we isolated from shiitake mushroom were nanoparticles that
contain cargos including RNAs, proteins, and lipids.
2.4.3 S-ELNs were taken up by macrophages
To assess whether S-ELNs were taken up by macrophages, we treated macrophages
with either RNA-labeled S-ELNs or lipid-labeled S-ELNs at different doses. The results
showed that the fluorescence of both RNA-labeled S-ELNs and lipid-labeled S-ELNs were
detected in macrophages and fluorescence intensity was increased with dose of S-ELNs
(Figure 4A, 4B), suggesting that S-ELNs, including the cargos inside of S-ELNs, were
taken up by macrophages and the uptake was increased in a dose-dependent manner.
2.4.4 S-ELNs suppressed the NLRP3 inflammasome activated by a range of stimuli
Besides FFA, the NLRP3 inflammasome can be activated by other stimuli,
including alum, nigericin and ATP (70,216,217). We further tested whether S-ELNs had
effects on the NLRP3 inflammasome activated by alum, nigericin or ATP. Macrophages
were treated with S-ELNs for 16 h. S-ELNs-primed macrophages were treated with LPS
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for 3 h and then were activated with nigericin or ATP for 30 minutes, or alum for 5 h.
Caspase-1 autocleavage and IL-1β secretion were measured using western blot and ELISA,
respectively. Results showed that S-ELNs significantly suppressed caspase-1 autocleavage
and IL-1β secretion when the NLRP3 inflammasome is activated by alum, nigericin and
ATP (Figure 5A, 5B, 5C). Taken together, S-ELNs had broadly inhibitory effects on the
NLRP3 inflammasome activated by different stimuli.
2.4.5 S-ELNs blocked ASC speck formation
ASC subunit is a key component involved in the assembly of NLRP3
inflammasome and ASC contains CARD domain which is responsible for recruiting
caspase-1 (61). After stimulation, ASC is recruited by NLRP3 and subsequently form
specks in the perinuclear area of the cell. Therefore, ASC specks could be used as an
indicator of inflammasome assembly (62,63). To determine the effects of S-ELNs on
inflammasome assembly, we assessed ASC speck formation with or without S-ELNs
treatment in macrophages. ASC specks were formed when NLRP3 inflammasome was
activated by FFA (Figure 6A, 6B). However, the number of ASC specks decreased
significantly when macrophages were pre-incubated with S-ELNs (Figure 6A, 6B). This
result indicated that S-ELN inhibited assembly of the NLRP3 inflammasome.
2.4.6 S-ELNs decreased both protein and mRNA levels of the Il1b gene and
decreased transcription levels of some inflammasome subunits
Activation of the NLRP3 inflammasome requires two signals: the first signal
stimulates transcription of the Nlrp3 and I1b genes; the second signal activates the
assembly of NLRP3 inflammasome subunits including NLRP3, ASC and caspase-1,
leading to the caspase-1 autocleavage and generation of mature IL-1β (61). Here, we
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assessed the effects of S-ELNs on both protein and mRNA levels of the Il1b, Nlrp3, Pycard
(Asc), and caspase-1 genes. After 16 h incubation with S-ELNs at different concentrations,
macrophages were treated with LPS plus FFA to activate the NLRP3 inflammasome. We
first measured the protein levels of NLRP3 inflammasome subunits using western blot. As
shown in Figure 7A, S-ELN treatment significantly suppressed the protein levels of proIL1β, but had marginal impact on protein levels of inflammasome subunits NLRP3,
caspase-1, ASC or inflammasome mediator NIMA-related kinases 7 (Nek7) (218). We
further tested whether S-ELNs have any inhibitory effect on mRNA levels of the Nlrp3,
Pycard, caspase1, and Il1b genes after NLRP3 inflammasome was activated using LPS
plus FFA. The qPCR results showed that S-ELNs suppressed transcription of the Il1b,
caspase1 and Nlrp3 genes (Figure 7B, 7D, and 7E). S-ELNs treatment slightly decreased
expression of the Pycard gene, but the effects were not statistically significant (Figure 7C).
When the NLRP3 inflammasome was activated using LPS plus ATP, S-ELNs dramatically
inhibited the protein level of pro-IL1β, but had no impact on protein levels of
inflammasome subunits or mediator (Figure 8A). At the transcription level, S-ELNs
strongly inhibited transcription of the Il1b, Pycard and caspase1 genes (Figure 8C, 8D,
8E), but did not affect expression of the Nlrp3 gene (Figure 8B). Collectively, these results
indicated that S-ELNs decreased both protein and mRNA levels of the Il1b gene and
decreased transcription levels of some inflammasome subunits.
2.4.7 Lipids in S-ELNs were identified as active agents that inhibit activation of the
NLRP3 inflammasome
To identify which category of biomolecules in S-ELNs has biological activity on
inhibiting activation of the NLRP3 inflammasome, S-ELNs were subjected to different
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treatment. S-ELNs were heated at 95 C for 10 min to denature proteins. RNAs in S-ELNs
were depleted by bath sonication plus RNase treatment. Bath sonication disrupts membrane
of ELNs and subsequently RNase can reach RNAs in the vesicles to catalyze the
degradation of RNAs (156,219,220). To study the functional significance of lipids in SELNs, the total lipids of S-ELNs were extracted, dried, and assembled into liposomes.
Macrophages were treated with protein-denatured S-ELNs, RNA-depleted S-ELNs and
liposomes prepared from S-ELN lipids for 16 h, respectively. Afterwards, LPS plus FFA
were used to activate the NLRP3 inflammasome in macrophages. Protein-denatured SELNs still had inhibitory effects on caspase-1 autocleavage and IL-1β secretion (Figure
9A), indicating proteins in S-ELNs are not the active cargos that inhibit activation of the
NLRP3 inflammasome. The inhibition of caspase-1 autocleavage and IL-1β secretion was
not dramatically affected after removal of most RNAs in S-ELNs (Figure 9B), which
suggested that RNAs in S-ELNs are not necessary for the inhibition of NLRP3
inflammasome activation. The inhibitory effect of S-ELN derived liposomes was as strong
as that of intact S-ELNs on caspase-1 autocleavage and IL-1β secretion (Figure 10). These
results suggested that the active biomolecules in S-ELNs with anti-inflammasome
functions were lipids rather than proteins and RNAs.
2.5 Discussion
In this study, we isolated and characterized ELNs from shiitake mushroom. We
showed that S-ELNs are nanoparticles that contain cargos including RNAs, proteins, and
lipids for the first time. Thus, S-ELNs had similar size and content as the mammalian
exosomes (35). S-ELNs were taken up by macrophages in a dose-dependent manner.
Importantly, we demonstrated the inhibitory effects of S-ELNs on caspase-1 autocleavage
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and IL-1β secretion when NLRP3 inflammasome was activated by FFA. S-ELNs also
inhibited the NLRP3 inflammasome activated by a range of stimuli, including alum,
nigericin and ATP. S-ELNs blocked assembly of the NLRP3 inflammasome. In addition,
S-ELNs inhibited the protein and mRNA levels of the Il1b gene. Furthermore, we identified
lipids in S-ELNs as the activate cargos that inhibit caspase-1 autocleavage and IL-1β
secretion. Collectively, our results showed that S-ELNs strongly inhibited the NLRP3
inflammasome activation.
Mushrooms have been demonstrated to have immune-modulatory properties to go
against various diseases including diabetes, cancer, chronic hepatitis and arteriosclerosis
(221). The effects of mushrooms or their extracts on the NLRP3 inflammasome activation
have also been studied. Some mushrooms, such as almond mushroom (Agaricus blazei
Murill), Turkey tail (Trametes Versicolor) and lentinan from shiitake mushroom (Lentinus
edodes), have been reported to activate the NLRP3 inflammasome, and therefore lead to
inflammatory cell death (222-224). However, some of other mushrooms like golden oyster
mushroom (Pleurotus citrinopileatus) inhibited NLRP3 inflammasome activation (225).
Thus, we decided to investigate the role of mushroom-derived ELNs in the NLRP3
inflammasome activation. We evaluated the effects of six mushroom-derived ELNs on the
NLRP3 inflammasome activation. Interestingly, different kinds of mushroom-derived
ELNs have different effects on the NLRP3 inflammasome activation. Among the
mushroom-derived ELNs we tested, S-ELNs were the only one that strongly inhibited
caspase-1 autocleavage and IL-1β secretion (Figure 2F). Unlike S-ELNs, White beachderived ELNs, brown beach-derived ELNs and king-derived ELNs did not show significant
effects on both caspase-1 autocleavage and IL-1β secretion (Figure 2A, 2B, 2C). We
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reasoned that these three mushroom-derived ELNs might lack some specific biomolecules
that only present in S-ELNs. Although both white common-derived ELNs and brown
common-derived ELNs significantly inhibited IL-1β secretion, they had no effects on
caspase-1 autocleavage (Figure 2D, 2E).
S-ELNs have similar shape and size (Figure 3A, 3B) as those of other dietary ELNs
(34). RNAs, proteins, and lipids in S-ELNs were extracted and characterized in detail
(Figure 3C, 3D, 3E). Thus, we considered S-ELNs as exosome-like nanoparticles (ELNs)
that contain RNAs, protein, and lipids. Furthermore, we confirmed that macrophages were
able to take up RNA-labeled and lipid-labeled S-ELNs (Figure 4A, 4B). However, the
mechanism of this uptake is unknown. It has been suggested that exosomes are taken up
by cells through endocytosis and micropinocytosis (226). In the future study, we will
explore the mechanism underlying how macrophages take up S-ELNs.
The NLRP3 inflammasome is activated by a broad range of stimuli including FFAs,
alum, nigericin and ATP (70,216,217). Here, we demonstrated the inhibitory effects of SELNs on the NLRP3 inflammasome activated by FFA, alum, nigericin and ATP (Figure
2F, 5A, 5B, 5C), indicating S-ELNs have a broad inhibitory effect on the NLRP3
inflammasome activation. Importantly, S-ELNs seem to have multiple targets that
converge on the NLRP3 inflammasome and thus synergistically or additively suppress
NLRP3 inflammasome activity. First, S-ELNs inhibited assembly of the inflammasome
(Figure 6A, 6B), Second, S-ELNs inhibited both protein and mRNA levels of the Il1b gene
when macrophages were activated by LPS plus FFA or LPS plus ATP (Figure 7A, 7E, 8A,
8E), suggesting the potential role of S-ELNs in attenuating NF-B pathway. Finally, SELNs inhibited expression of some inflammasome subunits (Figure 7B, 7D, 8C, 8D).
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Lentinan extracted from shiitake mushroom has been shown to inhibit AIM2
inflammasome activation, but not NLRP3 inflammasome (227). In the future study, we
will evaluate the effects of S-ELNs on activation of other inflammasomes. Together, these
results provide a basis to further study the mechanisms underlying how S-ELNs inhibit
NLRP3 inflammasome activation.
Exosomes and dietary ELNs participate in the intercellular communication or even
interspecies communication by delivering their cargoes to target cells (34). Evidence has
demonstrated that the RNA cargos in exosomes or ELNs have biological activity (154).
We found that the inhibitory effect of lipids from S-ELNs was as strong as that of intact SELNs (Figure 10). Further identification of specific lipid components in S-ELNs that
inhibit NLRP3 inflammasome activation is needed. In addition, further study is warranted
to demonstrate the inhibitory effects of lipids in S-ELNs on NLRP3 inflammasome
activation in vivo.
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CHAPTER 3. DISCUSSION, LIMITATION, AND FUTURE STUDIES
3.1 Discussion
The NLRP3 inflammasome is a multiprotein complex containing NLRP3, ASC and
capase-1 (65). It is activated by a variety of exogenous PAMPs and endogenous DAMPs
and therefore plays an important role in immune system (65). However, dysregulated or
excessive activation of the NLRP3 inflammasome contributes to the pathogenesis of many
diseases including Alzheimer’s disease, type 2 diabetes, and gout (213-215). Accumulating
evidence has demonstrated that inhibition of the NLRP3 inflammasome has high
therapeutic potential for treatment of NLRP3 inflammasome-related diseases (213,214).
Exosomes are bilayer membrane-enclosed nanoparticles containing RNAs, proteins and
lipids (23). They play an important role in intercellular communication (34,106). Besides
endogenous exosomes, exosomes or exosome-like nanoparticles (ELNs) obtained from
dietary sources have been identified and characterized (34,228), and their therapeutic
potential for treatment of diseases has also been studied (30). A few studies have suggested
that RNAs in bovine milk exosomes affect the biological activities of target cells (220,229),
but the functional significance of cargos from edible plant-derived ELNs in consumers are
still controversial. In addition, only a few edible plant-derived ELNs have been studied and
many more dietary ELNs await further investigation.
3.1.1 Inhibition of the NLRP3 inflammasome
Inflammation protects body against exogenous pathogens and this function is
beneficial to human health (230). However, aberrant inflammation contributes to the
pathogenesis of diseases (230). Dysregulated or excessive activation of the NLRP3
inflammasome leads to continuous release of IL-1β, which is associated with a variety of
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chronic inflammatory diseases, including diabetes and atherosclerosis (11,231). IL-1β
inhibitors have been utilized in treating these diseases in clinical trials (232), but these
inhibitors showed modest effects possibly because they only inhibit one downstream event
of the NLRP3 inflammasome (61). Some molecules have been discovered to inhibit
NLRP3 inflammasome activation in vivo or in vitro. For example, the neurotransmitter
dopamine inhibited NLRP3 inflammasome activation via dopamine D1 receptor in
macrophages. This study provides a promising approach for preventing neuroinflammation
(233). Similarly, nitric oxide has been demonstrated to inhibit NLRP3 inflammasome
activation through stabilizing mitochondria (234,235). A small-molecule chemical called
MCC950 inhibited NLRP3 inflammation activation and protected mice from autoimmune
diseases and cognitive decline (18,236). BAY11-7082 protected mice from spinal cord
injury-induced lung injury by inhibiting NLRP3 inflammasome activation (237). Other
pharmaceutical NLRP3 inhibitors including IFM-514, IFM-632 and CRID3 have also been
investigated for their efficacy in the retinal pigment epithelium cells, thereby providing
promising agents for treatment of atrophic age-related macular degeneration (238). Aspirin
has been widely used in clinical treatment due to its anti-inflammatory effect. It has been
demonstrated to have inhibitory effects on activation of the NLRP3 inflammasome via
suppression of ROS (239).
Besides endogenous molecules and pharmacological molecules, some natural
molecules from herbs or foods have also been reported to have inhibitory effects on NLRP3
inflammasome activation. Kaempferol found in herbs has been identified as a potential
inhibitor that suppresses NLRP3 inflammasome activation via ubiquitin-autolysosome
pathway (240). As a result, kaempferol treatment reduced neuroinflammation and
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protected mice against neurodegeneration in Parkinson’s disease (240). Another foodborne molecule naringenin also inhibited NLRP3 inflammasome activation and therefore
protected against LPS-induced dopamine neurotoxicity in Parkinson’s disease (241).
Laurus nobilis leaf extract suppressed NLRP3 inflammasome activation in macrophages
possibly through 1,8-cineole, a major component of this leaf extract (242). When L. nobilis
leaf extract were administered to mice, they reduced expression of proinflammatory
cytokine genes in an acute lung injury murine model (242). Despite these interesting
findings, the efficacy and safety of these molecules for long-term usage in chronic diseases
such as diabetes have not been evaluated. Therefore, there is a need to expand the pool of
inflammasome inhibitors. Mushrooms have potential in inhibition of NLRP3
inflammasome activation (225), but more direct evidence is needed to support such
functions. Our results demonstrate for the first time that S-ELNs strongly inhibit NLRP3
inflammasome activation in macrophages (Figure 2F). Thus, S-ELNs represent a new
promising agent that blocks NLRP3 inflammasome activation.
3.1.2 Therapeutic potential of dietary exosome-like nanoparticles (ELNs)
Dietary ELNs have been reported as promising therapeutic approaches for
treatment of diseases. Grape-derived ELNs were taken up by intestinal macrophages and
intestinal stem cells, indicating a possible role of dietary ELNs in mediating interspecies
communication (34). Grape-derived ELNs promoted the growth of Lgr5+ intestinal stem
cells, therefore protecting mice against DSS-induced colitis (30). Ginger-derived ELNs
also show anti-inflammatory property, because ginger-derived ELNs ameliorated disease
symptoms in DDS-induced colitis mouse models (243). In addition, ginger-derived ELNs
mediated nuclear factor erythroid 2-related factor (Nrf2) activation in liver cells, and
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therefore protected mice against alcohol-induced liver injury (244). Unlike grape-derived
ELNs, ginger-derived ELNs were taken up by intestinal epithelial cells (243). Bovine milk
exosomes (BMEs) regulated gene expression and the levels of amino acids in skeletal
muscles in mice (227). In addition, BMEs affected the cognitive performance and gut
microbiome in mice (38,245). BMEs enhanced mucin production by increasing goblet cell
activity (246). In addition, BMEs promoted protein synthesis by inducing expression of
GRP94, a intraluminal endoplasmic reticulum chaperones involved in protein folding (246).
As a result, BME treatment protected mice against necrotizing enterocolitis (NEC)-induced
intestinal injury (246). Recently, a study from our laboratory suggested that ginger-derived
ELNs had strong inhibitory effect on NLRP3 inflammasome activation (247). Together,
dietary ELNs could regulate gene expression and activate functions of certain molecules at
the molecular level (219,246) and promote cell proliferation at the cellular level (30,246).
More importantly, dietary ELNs could protect mice against DSS-induced colitis, alcoholinduced liver injury and NEC-induced intestinal injury at the pathophysiological level
(30,244,246).
3.1.3 Biological activities of cargos in dietary ELNs
ELNs participate in the intercellular or interspecies communications by carrying
RNAs, proteins and lipids (34,106). RNA cargos in BMEs regulated gene expression in
target cells (220,229). The glycoproteins on the surface of BMEs play an important role in
the uptake process in human and rat intestinal cells (151). MicroRNAs in BMEs are mainly
distributed in intestinal mucosa, spleen, liver, heart and brain (155). This distribution
pattern is distinctive from intact BMEs (155). In our study, we confirmed S-ELNs as
exosome-like nanoparticles (ELNs) containing RNAs, proteins and lipids (Figure 3A-E).
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we also discovered that S-ELNs, including the cargos inside of S-ELNs, were taken up by
macrophages in a dose-dependent manner (Figure 4A, 4B). However, whether
glycoproteins of S-ELNs play a critical role in the uptake process has not been studied.
MicroRNAs in ginger-derived ELNs regulated the functions and motility of gut microbiota
in the mice (248), while lipids in grape-derived ELNs promoted proliferation of intestinal
stem cells and liposome-like nanoparticles assembled from lipids of grape-derived ELNs
play a crucial role in targeting intestinal stem cells (30). In addition, lipids from grapefruitderived ELNs have been utilized as a vector to deliver therapeutic agents for cancer
treatment, because these lipids do not cause cytotoxicity and inflammatory response (149).
Recently, lipids in ginger-derived ELNs have been demonstrated as active biomolecules
that inhibit NLRP3 inflammasome activation (247). Similarly, lipids in S-ELNs have also
been identified as bioactive agents that inhibit NLRP3 inflammasome activation in
macrophages (Figure 10A).
3.2 Limitation and future studies
Here, we list four limitations in the current study and how we plan to address them
in the future studies. Firstly, although we demonstrated the inhibitory effects of S-ELNs
on NLRP3 inflammasome activated by a range of stimuli in macrophages, the mechanism
underlying how S-ELNs inhibit NLRP3 inflammasome activation has not been studied.
We mentioned three upstream events involved in NLRP3 inflammasome activation in the
chapter 1: intracellular K+ efflux, reactive oxygen species (ROS) production, and
lysosomal destabilization and rupture. We will assess intracellular KCl, the production of
ROS and lysosomal dysfunction to demonstrate how S-ELNs inhibited NLRP3
inflammasome activation at the cellular level. Secondly, we identified lipids as the active
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agents that inhibit NLRP3 inflammasome activation. S-ELNs contain many different kinds
of lipids (Figure 3E). The specific lipid that is responsible for anti-inflammasome functions
has not been identified. To address this question, we plan to perform lipidomics analysis
of lipids in S-ELNs. Among six mushroom-derived ELNs we tested, five mushroomderived ELNs have no effects on caspase-1 autocleavage or IL-1β secretion (Figure 2A,
2B, 2C, 2D, 2E). We plant to choose one of these five inactive mushroom-derived ELNs
as a negative control. The lipidomes of active S-ELNs and inactive mushroom-derived
ELNs will be compared. The lipids specifically enriched in S-ELNs could be the potential
candidates, which will be tested individually for their effects on NLRP3 inflammasome
activation. Thirdly, we found that macrophages take up S-ELNs. Whether S-ELNs can be
taken up by intestinal cells and how S-ELNs are distributed in mice have not been
determined. Uptake, delivery and distribution of S-ELNs will be investigated in the future.
Finally, we confirmed the inhibitory effects of S-ELNs on NLRP3 inflammasome
activation in vitro, but the effects of S-ELNs on NLRP3 inflammasome activation in vivo
have not been evaluated. We will determine whether oral administration or intravenous
injection of S-ELNs could protect mice from NLRP3 inflammasome-related diseases. If SELNs reduce inflammation and NLRP3 inflammasome activity in mice, we will further
use Nlrp3-/- mice to confirm that anti-inflammatory functions of S-ELNs are mediated
through the NLRP3 inflammasome.
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Figure 1. Activation of the NLRP3 inflammasome. Activation of the NLRP3 inflammasome requires two
signals. Signal 1, such as LPS and TNFα, induces expression of the Nlrp3 and Il1b genes through toll-like
receptor (TLR)/nuclear factor (NF)-κB pathway; Signal 2, such as ATP, FFAs and crystals, triggers
assembly of the NLRP3 inflammasome. Activation of the NLRP3 inflammasome causes autocleavage of
caspase-1 to produce the active caspase-1, which cleaves pro-IL-1β and pro-IL18 into active IL-1β and IL18. The mature cytokines IL-1β and IL-18 are released outside of cells.
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Figure 2. S-ELNs strongly inhibited caspase-1 autocleavage and IL-1β secretion upon NLRP3
inflammasome activation. A-F. Macrophages were treated with mushroom-derived ELNs for 16 h and
then treated with LPS for 3 h, and finally activated with FFA for 12 h. Caspase-1 autocleavage and IL-1β
were measured using western blot and ELISA, respectively. Tubulin is used as a control to show equivalent
loading. P values were calculated: * P < 0.05; ** P < 0.01. Treatment groups (mushroom-derived
ELNs+LPS+FFA, white bars) were compared with the control group (LPS+FFA, black bar). A. White beach
mushroom (White buna shimeji). B. Brown beach mushroom (Brown buna shimeji). C. King mushroom
(Pleurotus eryngii). D. White common mushroom (White agaricus bisporus). E. Brown common mushroom
(Brown agaricus bisporus). F. Shiitake mushroom (Lentinus edodes).
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Figure 3. Characterization of S-ELNs
A. Size distribution and vesicle concentration of S-ELNs. B. scanning electron microscope images of SELNs. C. RNAs of S-ELNs with or without RNase treatment were separated in the 2% agarose gel. D.
Proteins extracted from S-ELNs were separated on the SDS-PAGE gel and stained using Coomassie
Brilliant Blue. E. lipids extracted from S-ELNs were separated on the TLC plate.
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Figure 4. S-ELNs were taken up by macrophages
A.B. Macrophages were incubated with RNA-labeled or lipid-labeled S-ELNs at different doses for 16 h.
The fluorescence was detected by confocal microscopy. A. Lipid-labeled S-ELNs were taken up by
macrophages. B. RNA-labeled S-ELNs were taken up by macrophages.
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Figure 5. S-ELNs suppressed NLRP3 inflammasome activated by a range of stimuli
A. S-ELNs suppressed alum-induced NLRP3 inflammasome activation. S-ELNs-primed BMDMs were
treated with LPS for 3 h, and then activated with Alum for 5h. B. S-ELNs suppressed nigericin-induced
NLRP3 inflammasome activation. S-ELNs-primed BMDMs were treated with LPS for 3 h, and then activated
with nigericin for 30 minutes. C. S-ELNs suppressed ATP-induced NLRP3 inflammasome activation. SELNs-primed BMDMs were treated with LPS for 3 h, and then activated with ATP for 30 minutes. Tubulin
is used as a control to show equivalent loading. * P < 0.05; ** P < 0.01. Treatment group (SELNs+LPS+stimuli, white bar) was compared with the control group (LPS+stimuli, black bar).
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Figure 6. S-ELNs blocked ASC speck formation
A. Immunofluorescence of ASC speck formation in macrophages stimulated with LPS+FFAs with or without
S-ELNs incubation. Caspase-1 inhibitor VX765 (10 µM) were added 30 min before FFAs was incubated
with cells. Yellow arrows indicate ASC specks. Anti-ASC rabbit antibody was used as primary antibody (1st
Ab) and Alexa Fluor 594 anti-rabbit antibody was used as secondary antibody (2nd Ab). B. Percentage of
ASC speck positive cells. * P < 0.05; ** P < 0.01. Treatment group (LPS+FFA+S-ELNs, white bar) was
compared with control group (LPS+FFA, black bar).
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Figure 7. S-ELNs suppressed pro-IL-1 protein level and expression of the Il1b, Nlrp3, and caspase1
genes when inflammasome is activated using LPS+FFA.
A-E. Macrophages were treated with S-ELNs for 16 h, and then treated with LPS for 3 h, and finally activated
with FFAs for 12h. Cells were collected for analysis of protein and mRNA levels, respectively. A. S-ELN
treatment significantly suppressed the protein level of pro-IL-1β. B. S-ELNs significantly suppressed
transcription of the Nlrp3 gene. C. S-ELNs slightly decreased expression of the Pycard gene. D. S-ELNs
significantly suppressed transcription of the caspase1 gene. E. S-ELNs significantly suppressed
transcription of the Il1b gene. * P < 0.05; ** P < 0.01. Treatment groups (S-ELNs+LPS+FFA, white bars)
were compared with the control group (LPS+FFA, black bar).
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Figure 8. S-ELNs suppressed pro-IL-1 protein level and expression of the Il1b, Pycard, and
caspase1 genes when inflammasome is activated using LPS+ATP.
A-E. Macrophages were treated with S-ELNs for 16 h, and then treated with LPS for 3 h, and finally activated
with ATP for 0.5 h. Cells were collected for analysis of protein and mRNA levels, respectively. A. S-ELNs
dramatically inhibited the protein level of pro-IL-1

β. B. S-ELNs had no impact on expression of the Nlrp3

gene. C. S-ELNs significantly inhibited transcription of the Pycard gene. D. S-ELNs significantly inhibited
transcription of the caspase1 gene. E. S-ELNs significantly inhibited transcription of the Il1b gene. * P <
0.05; ** P < 0.01. Treatment groups (S-ELNs+LPS+ATP, white bars) were compared with the control group
(LPS+ATP, black bar).
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Figure 9. Protein and RNAs in S-ELNs were not the major bioactive agents that inhibit NLRP3
inflammasome activation. A.B. Macrophages were incubated with S-ELNs that were subjected to
different treatments for 16 h, and then stimulated with LPS+FFA. A. Protein-denatured S-ELNs still had
inhibitory effects on caspase-1 autocleavage and IL-1β secretion. Proteins in S-ELNs were denatured
by heating at 95 C for 10 min. Macrophages were treated with 61010/ml of regular S-ELNs (reg) or
protein-denatured S-ELNs (heated). B. Removal of the majority of RNAs did not affect the inhibitory
effects of S-ELNs on caspase-1 autocleavage and IL-1β secretion. RNAs in S-ELNs were removed
through bath sonication plus RNase (S/R) treatment. Macrophages were treated with 61010/ml of
regular S-ELNs (reg) or RNA-depleted S-ELNs (S/R-treated). Tubulin is used as a control to show
equivalent loading. * P < 0.05; ** P < 0.01. Treatment groups (S-ELNs or protein-denatured S-ELNs or
RNA-depleted S-ELNs +LPS+FFA, white bars) were compared with the control group (LPS+FFA, black
bar).
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Figure 10. Lipids in S-ELNs were identified as bioactive agents that inhibit NLRP3 inflammasome
activation. Lipids from S-ELNs strongly inhibited caspase-1 autocleavage and IL-1β secretion. Lipids
were extracted from S-ELNs and then re-assembled into liposomes. Macrophages were treated with
regular S-ELNs (reg) or liposomes. Tubulin is used as a control to show equivalent loading. * P < 0.05;
** P < 0.01. Treatment groups (S-ELNs or liposomes+LPS+FFA, white bars) were compared with the
control group (LPS+FFA, black bar).
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APPENDIX:
Abbreviations
ApoE—apolipoprotein E
ASC— Apoptotic speck protein containing a caspase recruitment domain
ATP—Adenosine triphosphate
BMDM-Bone marrow-derived macrophages
BMEs—Bovine milk exosomes
CARD—Caspase recruitment domain
DAMPs—Damage-associated molecular patterns
DAPI—4′,6-diamidino-2-phenylindole
DHA—Docosahexaenoic acid
DSS—Dextran sulfate sodium
EGCG—Epigallocatechin-3-gallate
ELNs—exosome-like nanoparticles
EVs—Extracellular vesicles
FBS—Fetal bovine serum
FFA—Free fatty acid sodium palmitate
FFAs—Free fatty acids
HEPES—4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
HFD—High fat diet
Hprt—hypoxanthine guanine phosphoribosyl transferase
IFN γ— Interferon γ
IL-1β—Interleukin-1β
IL-2—Interleukin-2
IL-6—Interleukin-6
LPS—Lipopolysaccarides
LRRs—Leucine-rich repeats
MAPKs—mitogen-activated protein kinases
MHC—Major histocompatibility complex
NaCl—Sodium chloride
NEC—Necrotizing enterocolitis
NEK—NIMA-related kinases 7
NF-κB—Nuclear factor kappa B
NK-T cells—Natural killer T cells
NLRP3—NOD-like receptor family, pyrin domain containing 3
NLRs—NOD-like receptors
NOD/NACHT—Nucleotide-binding-and-oligomerization
Nrf2—nuclear factor erythroid 2-related factor
nt—Nucleotide
PAMPs—Pathogen-associated molecular patterns
PA—Palmitate
PBS—phosphate buffered saline
PI3K—phosphatidylinositol 3-kinase
Pro-IL-1β—Pro-interleukin-1β
PRRs— Pattern recognition receptors
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PSPC—Purple sweet potato color
PUFAs—polyunsaturated fatty acids
PVDF—Polyvinylidene difluoride
PYD—pyrin domain
qPCR—Quantitative polymerase chain reaction
ROS—Reactive oxygen species
SDS-PAGE—sodium dodecyl sulfate-polyacrylamide gel electrophoresis
SDS—Sodium dodecyl sulfate
S-ELNs—shiitake-derived exosome-like nanoparticles
SFAs—Saturated fatty acids
STAT3—Signal transducer and activator of transcription 3
TLC—thin-layer chromatography
TLR 2/4—toll-like receptor 2/4
TLRs—Toll-like receptors
TNFα—Tumor necrosis factor-α
UFAs—unsaturated fatty acids
γδ-T cells—gamma delta T cells

57
References
1. Chen, G. Y., & Nuñez, G. (2010). Sterile inflammation: sensing and reacting to damage.
Nature Reviews Immunology, 10(12), 826.
2. Medzhitov, R. (2008). Origin and physiological roles of inflammation. Nature, 454(7203),
428.
3. Feghali, C. A., & Wright, T. M. (1997). Cytokines in acute and chronic inflammation. Front
Biosci, 2(1), d12-d26.
4. Spencer, W. G. (1936). Celsus de medicina. The American Journal of the Medical
Sciences, 191(3), 424
5. Celsus, A. C. (1935). De Medicina. Spencer WG, trans. vol. 3.
6. Ryan, G. B., & Majno, G. (1977). Acute inflammation. A review. The American journal of
pathology, 86(1), 183.
7. Couzin-Frankel, J. (2010). Inflammation bares a dark side.
8. Takeuchi, O., & Akira, S. (2010). Pattern recognition receptors and inflammation. Cell,
140(6), 805820.
9. Franchi, L., Muñoz-Planillo, R., & Núñez, G. (2012). Sensing and reacting to microbes
through the inflammasomes. Nature immunology, 13(4), 325.
10. Lamkanfi, M., & Dixit, V. M. (2012). Inflammasomes and their roles in health and disease.
Annual review of cell and developmental biology, 28, 137-161.
11. Strowig, T., Henao-Mejia, J., Elinav, E., & Flavell, R. (2012). Inflammasomes in health and
disease. nature, 481(7381), 278.
12. Wang, X., Feuerstein, G. Z., Gu, J. L., Lysko, P. G., & Yue, T. L. (1995). Interleukin-1β
induces expression of adhesion molecules in human vascular smooth muscle cells and
enhances adhesion of leukocytes to smooth muscle cells. Atherosclerosis, 115(1), 89-98.
13. Bhaskar, V., Yin, J., Mirza, A. M., Phan, D., Vanegas, S., Issafras, H., ... & Kantak, S. S.
(2011). Monoclonal antibodies targeting IL-1 beta reduce biomarkers of atherosclerosis in
vitro and inhibit atherosclerotic plaque formation in Apolipoprotein E-deficient mice.
Atherosclerosis, 216(2), 313-320.
14. Boni-Schnetzler, M., Thorne, J., Parnaud, G., Marselli, L., Ehses, J. A., Kerr-Conte, J., ...
& Donath, M. Y. (2008). Increased interleukin (IL)-1β messenger ribonucleic acid
expression in β-cells of individuals with type 2 diabetes and regulation of IL-1β in human
islets by glucose and autostimulation. The Journal of Clinical Endocrinology & Metabolism,
93(10), 4065-4074.
15. Cook, G. P., Savic, S., Wittmann, M., & McDermott, M. F. (2010). The NLRP3
inflammasome, a target for therapy in diverse disease states. European journal of
immunology, 40(3), 631-634.
16. Vandanmagsar, B., Youm, Y. H., Ravussin, A., Galgani, J. E., Stadler, K., Mynatt, R. L., ...
& Dixit, V. D. (2011). The NLRP3 inflammasome instigates obesity-induced inflammation
and insulin resistance. Nature medicine, 17(2), 179.
17. Youm, Y. H., Adijiang, A., Vandanmagsar, B., Burk, D., Ravussin, A., & Dixit, V. D. (2011).
Elimination of the NLRP3-ASC inflammasome protects against chronic obesity-induced
pancreatic damage. Endocrinology, 152(11), 4039-4045.
18. Coll, R. C., Robertson, A. A., Chae, J. J., Higgins, S. C., Muñoz-Planillo, R., Inserra, M. C.,
... & Croker, D. E. (2015). A small-molecule inhibitor of the NLRP3 inflammasome for the
treatment of inflammatory diseases. Nature medicine, 21(3), 248.
19. Lee, Y., El Andaloussi, S., & Wood, M. J. (2012). Exosomes and microvesicles:
extracellular vesicles for genetic information transfer and gene therapy. Human molecular
genetics, 21(R1), R125-R134.
20. Raposo, G., & Stoorvogel, W. (2013). Extracellular vesicles: exosomes, microvesicles, and
friends. J Cell Biol, 200(4), 373-383.

58
21. Akers, J. C., Gonda, D., Kim, R., Carter, B. S., & Chen, C. C. (2013). Biogenesis of
extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic
bodies. Journal of neuro-oncology, 113(1), 1-11.
22. Shao, H., Im, H., Castro, C. M., Breakefield, X., Weissleder, R., & Lee, H. (2018). New
technologies for analysis of extracellular vesicles. Chemical reviews, 118(4), 1917-1950.
23. Ludwig, A. K., & Giebel, B. (2012). Exosomes: small vesicles participating in intercellular
communication. The international journal of biochemistry & cell biology, 44(1), 11-15.
24. Silva, A. M., Teixeira, J. H., Almeida, M. I., Gonçalves, R. M., Barbosa, M. A., & Santos, S.
G. (2017). Extracellular vesicles: immunomodulatory messengers in the context of tissue
repair/regeneration. European Journal of Pharmaceutical Sciences, 98, 86-95.
25. Raposo, G., Nijman, H. W., Stoorvogel, W., Liejendekker, R., Harding, C. V., Melief, C. J.,
& Geuze, H. J. (1996). B lymphocytes secrete antigen-presenting vesicles. Journal of
Experimental Medicine, 183(3), 1161-1172.
26. Dinkins, M. B., Dasgupta, S., Wang, G., Zhu, G., & Bieberich, E. (2014). Exosome
reduction in vivo is associated with lower amyloid plaque load in the 5XFAD mouse model
of Alzheimer's disease. Neurobiology of aging, 35(8), 1792-1800.
27. Singh, R., Pochampally, R., Watabe, K., Lu, Z., & Mo, Y. Y. (2014). Exosome-mediated
transfer of miR-10b promotes cell invasion in breast cancer. Molecular cancer, 13(1), 256.
28. An, Q., Hückelhoven, R., Kogel, K. H., & Van Bel, A. J. (2006). Multivesicular bodies
participate in a cell wall‐associated defence response in barley leaves attacked by the
pathogenic powdery mildew fungus. Cellular microbiology, 8(6), 1009-1019.
29. Regente, M., Pinedo, M., Elizalde, M., & de la Canal, L. (2012). Apoplastic exosome-like
vesicles: a new way of protein secretion in plants?. Plant signaling & behavior, 7(5), 544546.
30. Ju, S., Mu, J., Dokland, T., Zhuang, X., Wang, Q., Jiang, H., ... & Roth, M. (2013). Grape
exosome like nanoparticles induce intestinal stem cells and protect mice from DSS-induced
colitis. Molecular Therapy, 21(7), 1345-1357.
31. Cheruvanky, A., Zhou, H., Pisitkun, T., Kopp, J. B., Knepper, M. A., Yuen, P. S., & Star, R.
A. (2007). Rapid isolation of urinary exosomal biomarkers using a nanomembrane
ultrafiltration concentrator. American Journal of Physiology-Renal Physiology, 292(5),
F1657-F1661.
32. Nabhan, J. F., Hu, R., Oh, R. S., Cohen, S. N., & Lu, Q. (2012). Formation and release of
arrestin domain-containing protein 1-mediated microvesicles (ARMMs) at plasma
membrane by recruitment of TSG101 protein. Proceedings of the National Academy of
Sciences, 109(11), 4146-4151.
33. Arntz, O. J., Pieters, B. C., Oliveira, M. C., Broeren, M. G., Bennink, M. B., de Vries, M., ...
& van de Loo, F. A. (2015). Oral administration of bovine milk derived extracellular vesicles
attenuates arthritis in two mouse models. Molecular nutrition & food research, 59(9), 17011712.
34. Mu, J., Zhuang, X., Wang, Q., Jiang, H., Deng, Z. B., Wang, B., ... & Zhang, H. G. (2014).
Interspecies communication between plant and mouse gut host cells through edible plant
derived exosome‐like nanoparticles. Molecular nutrition & food research, 58(7), 15611573.
35. Sokolova, V., Ludwig, A. K., Hornung, S., Rotan, O., Horn, P. A., Epple, M., & Giebel, B.
(2011). Characterisation of exosomes derived from human cells by nanoparticle tracking
analysis and scanning electron microscopy. Colloids and Surfaces B: Biointerfaces, 87(1),
146-150.
36. Kusuma, R. J., Manca, S., Friemel, T., Sukreet, S., Nguyen, C., & Zempleni, J. (2016).
Human vascular endothelial cells transport foreign exosomes from cow's milk by
endocytosis. American Journal of Physiology-Cell Physiology, 310(10), C800-C807.

59
37. Sukreet, S., Zhang, H., Adamec, J., Cui, J., & Zempleni, J. (2016). Identification of
glycoproteins on the surface of Cow’s milk exosomes that mediate the uptake of exosomes
into human colon carcinoma Caco-2 Cells. The FASEB journal, 30(1_supplement), 125-1.
38. Mutai, E., Zhou, F., & Zempleni, J. (2017). Depletion of dietary bovine milk exosomes
impairs sensorimotor gating and spatial learning in C57BL/6 mice. The FASEB Journal,
31(1_supplement), 150-4.
39. Benmoussa, A., Lee, C. H. C., Laffont, B., Savard, P., Laugier, J., Boilard, E., ... & Provost,
P. (2016). Commercial dairy cow milk microRNAs resist digestion under simulated
gastrointestinal tract conditions. The Journal of nutrition, 146(11), 2206-2215.
40. Manca, S., Giraud, D., & Zempleni, J. (2017). The bioavailability and distribution of bovine
milk exosomes is distinct from that of their cargos in mice. The FASEB Journal,
31(1_supplement), 148-2.
41. Rathore, H., Prasad, S., & Sharma, S. (2017). Mushroom nutraceuticals for improved
nutrition and better human health: a review. PharmaNutrition, 5(2), 35-46.
42. Badalyan, S. (2012). Medicinal aspects of edible ectomycorrhizal mushrooms. In Edible
Ectomycorrhizal Mushrooms (pp. 317-334). Springer, Berlin, Heidelberg.
43. Elsayed, E. A., El Enshasy, H., Wadaan, M. A., & Aziz, R. (2014). Mushrooms: a potential
natural source of anti-inflammatory compounds for medical applications. Mediators of
inflammation, 2014.
44. Taofiq, O., Martins, A., Barreiro, M. F., & Ferreira, I. C. (2016). Anti-inflammatory potential
of mushroom extracts and isolated metabolites. Trends in Food Science & Technology, 50,
193-210.
45. Liu, K., Wang, J., Zhao, L., & Wang, Q. (2013). Anticancer, antioxidant and antibiotic
activities of mushroom Ramaria flava. Food and chemical toxicology, 58, 375-380.
46. Turkoglu, A., Duru, M. E., Mercan, N., Kivrak, I., & Gezer, K. (2007). Antioxidant and
antimicrobial activities of Laetiporus sulphureus (Bull.) Murrill. Food Chemistry, 101(1),
267-273.
47. Ooi, V. E. C., & Liu, F. (1999). A review of pharmacological activities of mushroom
polysaccharides. International Journal of Medicinal Mushrooms, 1(3).
48. Zaidman, B. Z., Yassin, M., Mahajna, J., & Wasser, S. P. (2005). Medicinal mushroom
modulators of molecular targets as cancer therapeutics. Applied Microbiology and
Biotechnology, 67(4), 453-468.
49. Jeong, S. C., Jeong, Y. T., Yang, B. K., Islam, R., Koyyalamudi, S. R., Pang, G., ... & Song,
C. H. (2010). White button mushroom (Agaricus bisporus) lowers blood glucose and
cholesterol levels in diabetic and hypercholesterolemic rats. Nutrition research, 30(1), 4956.
50. Kim, S. H., Thomas, M. J., Wu, D., Carman, C. V., Ordovás, J. M., & Meydani, M. (2019).
Edible Mushrooms Reduce Atherosclerosis in Ldlr−/− Mice Fed a High-Fat Diet. The
Journal of nutrition.
51. Adams, L. S., Chen, S., Phung, S., Wu, X., & Ki, L. (2008). White button mushroom
(Agaricus bisporus) exhibits antiproliferative and proapoptotic properties and inhibits
prostate tumor growth in athymic mice. Nutrition and cancer, 60(6), 744-756.
52. Kim, H., Cho, K. M., Gerelchuluun, T., Lee, J. S., Chung, K. S., & Lee, C. K. (2007). Lectins
isolated from mushroom Fomitella fraxinea enhance MHC-restricted exogenous antigen
presentation. Immune Network, 7(4), 197-202.
53. Bernardshaw, S., Johnson, E., & Hetland, G. (2005). An extract of the mushroom Agaricus
blazei Murill administered orally protects against systemic Streptococcus pneumoniae
infection in mice. Scandinavian Journal of Immunology, 62(4), 393-398.
54. Karasawa, T., Kawashima, A., Usui-Kawanishi, F., Watanabe, S., Kimura, H., Kamata, R.,
... & Tomoda, H. (2018). Saturated fatty acids undergo intracellular crystallization and
activate the NLRP3 inflammasome in macrophages. Arteriosclerosis, thrombosis, and
vascular biology, 38(4), 744-756.

60
55. L'homme, L., Esser, N., Riva, L., Scheen, A., Paquot, N., Piette, J., & Legrand-Poels, S.
(2013). Unsaturated fatty acids prevent activation of NLRP3 inflammasome in human
monocytes/macrophages. Journal of lipid research, 54(11), 2998-3008.
56. Yan, Y., Jiang, W., Spinetti, T., Tardivel, A., Castillo, R., Bourquin, C., ... & Zhou, R. (2013).
Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of
NLRP3 inflammasome activation. Immunity, 38(6), 1154-1163.
57. Yang, H., Xiao, L., Yuan, Y., Luo, X., Jiang, M., Ni, J., & Wang, N. (2014). Procyanidin B2
inhibits NLRP3 inflammasome activation in human vascular endothelial cells. Biochemical
pharmacology, 92(4), 599-606.
58. Sun, C., Fan, S., Wang, X., Lu, J., Zhang, Z., Wu, D., ... & Zheng, Y. (2015). Purple sweet
potato color inhibits endothelial premature senescence by blocking the NLRP3
inflammasome. The Journal of nutritional biochemistry, 26(10), 1029-1040.
59. Proell, M., Riedl, S. J., Fritz, J. H., Rojas, A. M., & Schwarzenbacher, R. (2008). The Nodlike receptor (NLR) family: a tale of similarities and differences. PloS one, 3(4), e2119.
60. Ting, J. P. Y., Lovering, R. C., Alnemri, E. S., Bertin, J., Boss, J. M., Davis, B. K., ... &
Hoffman, H. M. (2008). The NLR gene family: a standard nomenclature. Immunity, 28(3),
285-287.
61. Hernandez, J. C., Sirois, C. M., & Latz, E. (2011). Activation and regulation of the NLRP3
inflammasome. In The inflammasomes (pp. 197-208). Springer, Basel.
62. Bryan, N. B., Dorfleutner, A., Rojanasakul, Y., & Stehlik, C. (2009). Activation of
inflammasomes requires intracellular redistribution of the apoptotic speck-like protein
containing a caspase recruitment domain. The Journal of Immunology, 182(5), 3173-3182.
63. Stutz, A., Horvath, G. L., Monks, B. G., & Latz, E. (2013). ASC speck formation as a readout
for inflammasome activation. In The Inflammasome (pp. 91-101). Humana Press, Totowa,
NJ.
64. Schroder, K., Zhou, R., & Tschopp, J. (2010). The NLRP3 inflammasome: a sensor for
metabolic danger?. Science, 327(5963), 296-300.
65. Martinon, F. et al. (2002) The inflammasome: a molecular platform triggering activation of
inflammatory caspases and processing of proIL-b. Mol. Cell 10, 417–426 3.
66. Wang, L. et al. (2002) PYPAF7, a novel PYRIN-containing Apaf1- like protein that regulates
activation of NF-k B and caspase-1- dependent cytokine processing. J. Biol. Chem. 277,
29874– 29880.
67. Bergsbaken, T., Fink, S. L., & Cookson, B. T. (2009). Pyroptosis: host cell death and
inflammation. Nature Reviews Microbiology, 7(2), 99.
68. Sutterwala, F. S., Haasken, S., & Cassel, S. L. (2014). Mechanism of NLRP3
inflammasome activation. Annals of the New York Academy of Sciences, 1319(1), 82.
69. He, Y., Hara, H., & Núñez, G. (2016). Mechanism and regulation of NLRP3 inflammasome
activation. Trends in biochemical sciences, 41(12), 1012-1021.
70. COUILLIN, I., GOMBAULT, A., & Baron, L. (2013). ATP release and purinergic signaling
in NLRP3 inflammasome activation. Frontiers in immunology, 3, 414.
71. Muñoz-Planillo, R., Kuffa, P., Martínez-Colón, G., Smith, B. L., Rajendiran, T. M., & Núñez,
G. (2013). K+ efflux is the common trigger of NLRP3 inflammasome activation by bacterial
toxins and particulate matter. Immunity, 38(6), 1142-1153.
72. Perregaux, D., & Gabel, C. A. (1994). Interleukin-1 beta maturation and release in
response to ATP and nigericin. Evidence that potassium depletion mediated by these
agents is a necessary and common feature of their activity. Journal of Biological Chemistry,
269(21), 15195-15203.
73. Petrilli, V., Papin, S., Dostert, C., Mayor, A., Martinon, F., & Tschopp, J. (2007). Activation
of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell
death and differentiation, 14(9), 1583.

61
74. Pelegrin, P., & Surprenant, A. (2006). Pannexin‐1 mediates large pore formation and
interleukin‐1β release by the ATP‐gated P2X7 receptor. The EMBO journal, 25(21), 50715082.
75. Groß, C. J., Mishra, R., Schneider, K. S., Médard, G., Wettmarshausen, J., Dittlein, D. C.,
... & Magnani, G. (2016). K+ efflux-independent NLRP3 inflammasome activation by small
molecules targeting mitochondria. Immunity, 45(4), 761-773.
76. Cruz, C. M., Rinna, A., Forman, H. J., Ventura, A. L., Persechini, P. M., & Ojcius, D. M.
(2007). ATP activates a reactive oxygen species-dependent oxidative stress response and
secretion of proinflammatory cytokines in macrophages. Journal of Biological Chemistry,
282(5), 2871-2879.
77. Dostert, C., Pétrilli, V., Van Bruggen, R., Steele, C., Mossman, B. T., & Tschopp, J. (2008).
Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica.
Science, 320(5876), 674-677.
78. Bae, Y. S., Oh, H., Rhee, S. G., & Do Yoo, Y. (2011). Regulation of reactive oxygen species
generation in cell signaling. Molecules and cells, 32(6), 491-509.
79. van Bruggen, R., Köker, M. Y., Jansen, M., van Houdt, M., Roos, D., Kuijpers, T. W., & van
den Berg, T. K. (2010). Human NLRP3 inflammasome activation is Nox1-4 independent.
Blood, 115(26), 5398-5400.
80. Bauernfeind, F., Bartok, E., Rieger, A., Franchi, L., Núñez, G., & Hornung, V. (2011).
Cutting edge: reactive oxygen species inhibitors block priming, but not activation, of the
NLRP3 inflammasome. The Journal of Immunology, 187(2), 613-617.
81. Harrison, R. M., & Yin, J. (2000). Particulate matter in the atmosphere: which particle
properties are important for its effects on health?. Science of the total environment, 249(13), 85-101.
82. Hornung, V., Bauernfeind, F., Halle, A., Samstad, E. O., Kono, H., Rock, K. L., ... & Latz,
E. (2008). Silica crystals and aluminum salts activate the NALP3 inflammasome through
phagosomal destabilization. Nature immunology, 9(8), 847.
83. Franchi L, Núñez G. The Nlrp3 inflammasome is critical for aluminium hydroxide‐mediated
IL‐1β secretion but dispensable for adjuvant activity. European journal of immunology.
2008 Aug;38(8):2085-9.
84. Spranger, J., Kroke, A., Möhlig, M., Hoffmann, K., Bergmann, M. M., Ristow, M., ... &
Pfeiffer, A. F. (2003). Inflammatory cytokines and the risk to develop type 2 diabetes:
results of the prospective population-based European Prospective Investigation into
Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes, 52(3), 812-817.
85. Maedler, K., Dharmadhikari, G., Schumann, D. M., & Størling, J. (2009). Interleukin-1 beta
targeted therapy for type 2 diabetes. Expert opinion on biological therapy, 9(9), 1177-1188.
86. Maedler, K., Dharmadhikari, G., Schumann, D. M., & Størling, J. (2009). Interleukin-1 beta
targeted therapy for type 2 diabetes. Expert opinion on biological therapy, 9(9), 1177-1188.
87. Ehses, J. A., Perren, A., Eppler, E., Ribaux, P., Pospisilik, J. A., Maor-Cahn, R., ... &
Fontana, A. (2007). Increased number of islet-associated macrophages in type 2 diabetes.
Diabetes, 56(9), 2356-2370.
88. Riddle, M. C. (2003). sulfonylureas differ in effects on ischemic preconditioning—is it time
to retire glyburide?.
89. Lamkanfi, M., Mueller, J. L., Vitari, A. C., Misaghi, S., Fedorova, A., Deshayes, K., ... &
Dixit, V. M. (2009). Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. The Journal of
cell biology, 187(1), 61-70.
90. Ross, R. (1999). Atherosclerosis—an inflammatory disease. New England journal of
medicine, 340(2), 115-126.
91. Katz, S. S., Shipley, G. G., & Small, D. M. (1976). Physical chemistry of the lipids of human
atherosclerotic lesions. Demonstration of a lesion intermediate between fatty streaks and
advanced plaques. The Journal of clinical investigation, 58(1), 200-211.

62
92. Galea, J., Armstrong, J., Gadsdon, P., Holden, H., Francis, S. E., & Holt, C. M. (1996).
Interleukin-1β in coronary arteries of patients with ischemic heart disease. Arteriosclerosis,
thrombosis, and vascular biology, 16(8), 1000-1006.
93. Kirii, H., Niwa, T., Yamada, Y., Wada, H., Saito, K., Iwakura, Y., ... & Seishima, M. (2003).
Lack of interleukin-1β decreases the severity of atherosclerosis in ApoE-deficient mice.
Arteriosclerosis, thrombosis, and vascular biology, 23(4), 656-660.
94. Wang, R., Wang, Y., Mu, N., Lou, X., Li, W., Chen, Y., ... & Tan, H. (2017). Activation of
NLRP3 inflammasomes contributes to hyperhomocysteinemia-aggravated inflammation
and atherosclerosis in apoE-deficient mice. Laboratory Investigation, 97(8), 922.
95. Rajamäki, K., Lappalainen, J., Öörni, K., Välimäki, E., Matikainen, S., Kovanen, P. T., &
Eklund, K. K. (2010). Cholesterol crystals activate the NLRP3 inflammasome in human
macrophages: a novel link between cholesterol metabolism and inflammation. PloS one,
5(7), e11765.
96. Petrasek, J., Bala, S., Csak, T., Lippai, D., Kodys, K., Menashy, V., ... & Szabo, G. (2012).
IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in
mice. The Journal of clinical investigation, 122(10), 3476-3489.
97. Lebeaupin, C., Proics, E., De Bieville, C. H. D., Rousseau, D., Bonnafous, S., Patouraux,
S., ... & Saint-Paul, M. C. (2015). ER stress induces NLRP3 inflammasome activation and
hepatocyte death. Cell death & disease, 6(9), e1879.
98. Wree, A., Eguchi, A., McGeough, M. D., Pena, C. A., Johnson, C. D., Canbay, A., ... &
Feldstein, A. E. (2014). NLRP3 inflammasome activation results in hepatocyte pyroptosis,
liver inflammation, and fibrosis in mice. Hepatology, 59(3), 898-910.
99. Yang, G., Lee, H. E., & Lee, J. Y. (2016). A pharmacological inhibitor of NLRP3
inflammasome prevents non-alcoholic fatty liver disease in a mouse model induced by high
fat diet. Scientific reports, 6, 24399.
100.
Caby, M. P., Lankar, D., Vincendeau-Scherrer, C., Raposo, G., & Bonnerot, C.
(2005). Exosomal-like vesicles are present in human blood plasma. International
immunology, 17(7), 879-887.
101.
Pisitkun, T., Shen, R. F., & Knepper, M. A. (2004). Identification and proteomic
profiling of exosomes in human urine. Proceedings of the National Academy of Sciences,
101(36), 13368-13373.
102.
Michael, A., Bajracharya, S. D., Yuen, P. S., Zhou, H., Star, R. A., Illei, G. G., &
Alevizos, I. (2010). Exosomes from human saliva as a source of microRNA biomarkers.
Oral diseases, 16(1), 34-38.
103.
Admyre, C., Johansson, S. M., Qazi, K. R., Filén, J. J., Lahesmaa, R., Norman,
M., ... & Gabrielsson, S. (2007). Exosomes with immune modulatory features are present
in human breast milk. The Journal of immunology, 179(3), 1969-1978.
104.
Cocucci, E., Racchetti, G., & Meldolesi, J. (2009). Shedding microvesicles:
artefacts no more. Trends in cell biology, 19(2), 43-51.
105.
Szatanek, R., Baran, J., Siedlar, M., & Baj-Krzyworzeka, M. (2015). Isolation of
extracellular vesicles: determining the correct approach. International journal of molecular
medicine, 36(1), 11-17.
106.
Simons, M., & Raposo, G. (2009). Exosomes–vesicular carriers for intercellular
communication. Current opinion in cell biology, 21(4), 575-581.
107.
Ratajczak, J., Miekus, K., Kucia, M., Zhang, J., Reca, R., Dvorak, P., & Ratajczak,
M. Z. (2006). Embryonic stem cell-derived microvesicles reprogram hematopoietic
progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia,
20(5), 847.
108.
Choi, D. S., Park, J. O., Jang, S. C., Yoon, Y. J., Jung, J. W., Choi, D. Y., ... & Lee,
K. H. (2011). Proteomic analysis of microvesicles derived from human colorectal cancer
ascites. Proteomics, 11(13), 2745-2751.

63
109.
Miguet, L., Pacaud, K., Felden, C., Hugel, B., Martinez, M. C., Freyssinet, J. M., ...
& Mauvieux, L. (2006). Proteomic analysis of malignant lymphocyte membrane
microparticles using double ionization coverage optimization. Proteomics, 6(1), 153-171.
110.
Melo, S. A., Luecke, L. B., Kahlert, C., Fernandez, A. F., Gammon, S. T., Kaye, J.,
... & Reissfelder, C. (2015). Glypican-1 identifies cancer exosomes and detects early
pancreatic cancer. Nature, 523(7559), 177.
111.
Kowal, J., Arras, G., Colombo, M., Jouve, M., Morath, J. P., Primdal-Bengtson, B.,
... & Théry, C. (2016). Proteomic comparison defines novel markers to characterize
heterogeneous populations of extracellular vesicle subtypes. Proceedings of the National
Academy of Sciences, 113(8), E968-E977.
112.
Lunavat, T. R., Cheng, L., Kim, D. K., Bhadury, J., Jang, S. C., Lässer, C., ... &
Hill, A. F. (2015). Small RNA deep sequencing discriminates subsets of extracellular
vesicles released by melanoma cells–Evidence of unique microRNA cargos. RNA biology,
12(8), 810-823.
113.
Huang, X., Yuan, T., Tschannen, M., Sun, Z., Jacob, H., Du, M., ... & Kohli, M.
(2013). Characterization of human plasma-derived exosomal RNAs by deep sequencing.
BMC genomics, 14(1), 319.
114.
Thind, A., & Wilson, C. (2016). Exosomal miRNAs as cancer biomarkers and
therapeutic targets. Journal of extracellular vesicles, 5(1), 31292.
115.
Batagov, A. O., & Kurochkin, I. V. (2013). Exosomes secreted by human cells
transport largely mRNA fragments that are enriched in the 3′-untranslated regions. Biology
direct, 8(1), 12.
116.
Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J. J., & Lötvall, J. O.
(2007). Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of
genetic exchange between cells. Nature cell biology, 9(6), 654.
117.
Montecalvo, A., Larregina, A. T., Shufesky, W. J., Stolz, D. B., Sullivan, M. L.,
Karlsson, J. M., ... & Milosevic, J. (2012). Mechanism of transfer of functional microRNAs
between mouse dendritic cells via exosomes. Blood, 119(3), 756-766.
118.
Wang, C., Zhang, C., Liu, L., Xi, A., Chen, B., Li, Y., & Du, J. (2017). Macrophagederived mir-155-containing exosomes suppress fibroblast proliferation and promote
fibroblast inflammation during cardiac injury. Molecular Therapy, 25(1), 192-204.
119.
Lässer, C. (2012). Exosomal RNA as biomarkers and the therapeutic potential of
exosome vectors. Expert opinion on biological therapy, 12(sup1), S189-S197.
120.
Hu, G., Drescher, K. M., & Chen, X. (2012). Exosomal miRNAs: biological
properties and therapeutic potential. Frontiers in genetics, 3, 56.
121.
Huang, X., Yuan, T., Liang, M., Du, M., Xia, S., Dittmar, R., ... & Tan, W. (2015).
Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate
cancer. European urology, 67(1), 33-41.
122.
Laulagnier, K., Motta, C., Hamdi, S., Sébastien, R. O. Y., Fauvelle, F., Pageaux,
J. F., ... & Record, M. (2004). Mast cell-and dendritic cell-derived exosomes display a
specific lipid composition and an unusual membrane organization. Biochemical Journal,
380(1), 161-171.
123.
Llorente, A., Skotland, T., Sylvänne, T., Kauhanen, D., Róg, T., Orłowski, A., ... &
Sandvig, K. (2013). Molecular lipidomics of exosomes released by PC-3 prostate cancer
cells. Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids, 1831(7),
1302-1309.
124.
Needham D, Nunn RS. Elastic deformation and failure of lipid bilayer membranes
containing cholesterol. Biophysical journal. 1990 Oct 1;58(4):997-1009.
125.
Abi-Rizk G, Besson F. Interactions of Triton X-100 with sphingomyelin and
phosphatidylcholine monolayers: influence of the cholesterol content. Colloids and
Surfaces B: Biointerfaces. 2008 Oct 15;66(2):163-7.

64
126.
Miyanishi, M., Tada, K., Koike, M., Uchiyama, Y., Kitamura, T., & Nagata, S.
(2007). Identification of Tim4 as a phosphatidylserine receptor. Nature, 450(7168), 435.
127.
Tkach, M., & Thery, C. (2016). Communication by extracellular vesicles: where we
are and where we need to go. Cell, 164(6), 1226-1232.
128.
Singer, S. J. (1992). Intercellular communication and cell-cell adhesion. Science,
255(5052), 1671-1677.
129.
Mathivanan, S., Ji, H., & Simpson, R. J. (2010). Exosomes: extracellular organelles
important in intercellular communication. Journal of proteomics, 73(10), 1907-1920.
130.
Andaloussi, S. E., Mäger, I., Breakefield, X. O., & Wood, M. J. (2013). Extracellular
vesicles: biology and emerging therapeutic opportunities. Nature reviews Drug discovery,
12(5), 347.
131.
Gatti, S., Bruno, S., Deregibus, M. C., Sordi, A., Cantaluppi, V., Tetta, C., &
Camussi, G. (2011). Microvesicles derived from human adult mesenchymal stem cells
protect against ischaemia–reperfusion-induced acute and chronic kidney injury.
Nephrology Dialysis Transplantation, 26(5), 1474-1483.
132.
Royo, F., Schlangen, K., Palomo, L., Gonzalez, E., Conde-Vancells, J., Berisa, A.,
... & Falcon-Perez, J. M. (2013). Transcriptome of extracellular vesicles released by
hepatocytes. PloS one, 8(7), e68693.
133.
Chivet, M., Hemming, F., Fraboulet, S., & Sadoul, R. (2012). Emerging role of
neuronal exosomes in the central nervous system. Frontiers in physiology, 3, 145.
134.
Alexander, M., Hu, R., Runtsch, M. C., Kagele, D. A., Mosbruger, T. L.,
Tolmachova, T., ... & O’Connell, R. M. (2015). Exosome-delivered microRNAs modulate
the inflammatory response to endotoxin. Nature communications, 6, 7321.
135.
Kim, S. H., Bianco, N., Menon, R., Lechman, E. R., Shufesky, W. J., Morelli, A. E.,
& Robbins, P. D. (2006). Exosomes derived from genetically modified DC expressing FasL
are anti-inflammatory and immunosuppressive. Molecular therapy, 13(2), 289-300.
136.
McDonald, M. K., Tian, Y., Qureshi, R. A., Gormley, M., Ertel, A., Gao, R., ... & Ajit,
S. K. (2014). Functional significance of macrophage-derived exosomes in inflammation
and pain. PAIN®, 155(8), 1527-1539.
137.
Bretz, N. P., Ridinger, J., Rupp, A. K., Rimbach, K., Keller, S., Rupp, C., ... &
Sammar, M. (2013). Body fluid exosomes promote secretion of inflammatory cytokines in
monocytic cells via Toll-like receptor signaling. Journal of Biological Chemistry, 288(51),
36691-36702.
138.
Zhao, H., Shang, Q., Pan, Z., Bai, Y., Li, Z., Zhang, H., ... & Wang, Q. (2018).
Exosomes from adipose-derived stem cells attenuate adipose inflammation and obesity
through polarizing M2 macrophages and beiging in white adipose tissue. Diabetes, 67(2),
235-247.
139.
Song, J., Huang, J., Chen, X., Teng, X., Song, Z., Xing, Y., ... & Hu, S. (2016).
Donor-derived exosomes induce specific regulatory T cells to suppress immune
inflammation in the allograft heart. Scientific reports, 6, 20077.
140.
Marcilla, A., Martin-Jaular, L., Trelis, M., de Menezes-Neto, A., Osuna, A., Bernal,
D., ... & del Portillo, H. A. (2014). Extracellular vesicles in parasitic diseases. Journal of
extracellular vesicles, 3(1), 25040.
141.
Anderson, H. C., Mulhall, D., & Garimella, R. (2010). Role of extracellular
membrane vesicles in the pathogenesis of various diseases, including cancer, renal
diseases, atherosclerosis, and arthritis. Laboratory investigation, 90(11), 1549.
142.
Rak, J., & Guha, A. (2012). Extracellular vesicles–vehicles that spread cancer
genes. Bioessays, 34(6), 489-497.
143.
Boulanger, C. M., Loyer, X., Rautou, P. E., & Amabile, N. (2017). Extracellular
vesicles in coronary artery disease. Nature reviews cardiology, 14(5), 259.

65
144.
Amabile, N., Rautou, P. E., Tedgui, A., & Boulanger, C. M. (2010, November).
Microparticles: key protagonists in cardiovascular disorders. In Seminars in thrombosis and
hemostasis (Vol. 36, No. 08, pp. 907-916). © Thieme Medical Publishers.
145.
Withrow, J., Murphy, C., Liu, Y., Hunter, M., Fulzele, S., & Hamrick, M. W. (2016).
Extracellular vesicles in the pathogenesis of rheumatoid arthritis and osteoarthritis. Arthritis
Research & Therapy, 18(1), 286.
146.
Moon, P. G., Lee, J. E., Cho, Y. E., Lee, S. J., Jung, J. H., Chae, Y. S., ... & Baek,
M. C. (2016). Identification of developmental endothelial locus-1 on circulating extracellular
vesicles as a novel biomarker for early breast cancer detection. Clinical Cancer Research,
22(7), 1757-1766.
147.
Wang, B., Zhuang, X., Deng, Z. B., Jiang, H., Mu, J., Wang, Q., ... & Yan, J. (2014).
Targeted drug delivery to intestinal macrophages by bioactive nanovesicles released from
grapefruit. Molecular Therapy, 22(3), 522-534.
148.
Wang, Q., Ren, Y., Mu, J., Egilmez, N. K., Zhuang, X., Deng, Z., ... & Zhang, H. G.
(2015). Grapefruit-derived nanovectors use an activated leukocyte trafficking pathway to
deliver therapeutic agents to inflammatory tumor sites. Cancer research, 75(12), 25202529.
149.
Wang, Q., Zhuang, X., Mu, J., Deng, Z. B., Jiang, H., Zhang, L., ... & Zhang, H. G.
(2013). Delivery of therapeutic agents by nanoparticles made of grapefruit-derived lipids.
Nature communications, 4, 1867.
150.
Zhou, Q., Li, M., Wang, X., Li, Q., Wang, T., Zhu, Q., ... & Li, X. (2012). Immunerelated microRNAs are abundant in breast milk exosomes. International journal of
biological sciences, 8(1), 118.
151.
Wolf, T., Baier, S. R., & Zempleni, J. (2015). The intestinal transport of bovine milk
exosomes is mediated by endocytosis in human colon carcinoma Caco-2 cells and rat
small intestinal IEC-6 cells. The Journal of nutrition, 145(10), 2201-2206.
152.
Sun, Q., Chen, X., Yu, J., Zen, K., Zhang, C. Y., & Li, L. (2013). Immune
modulatory function of abundant immune-related microRNAs in microvesicles from bovine
colostrum. Protein & cell, 4(3), 197-210.
153.
Zhou, F., Paz, H. A., Shu, J., Sadri, M., Juan, C. U. I., Fernando, S., & ZEMPLENI,
J. (2018). Dietary Bovine Milk Exosomes Elicit Changes in Microbial Communities in
C57BL/6 Mice. bioRxiv, 356048.
154.
Leiferman, A., Shu, J., Grove, R., Cui, J., Adamec, J., & Zempleni, J. (2018). A diet
defined by its content of bovine milk exosomes and their RNA cargos has moderate effects
on gene expression, amino acid profiles and grip strength in skeletal muscle in C57BL/6
mice. The Journal of nutritional biochemistry, 59, 123-128.
155.
Manca, S., Upadhyaya, B., Mutai, E., Desaulniers, A. T., Cederberg, R. A., White,
B. R., & Zempleni, J. (2018). Milk exosomes are bioavailable and distinct microRNA cargos
have unique tissue distribution patterns. Scientific reports, 8(1), 11321.
156.
Nordgren, T. M., Heires, A. J., Zempleni, J., Swanson, B. J., Wichman, C., &
Romberger, D. J. (2019). Bovine milk-derived extracellular vesicles enhance inflammation
and promote M1 polarization following agricultural dust exposure in mice. The Journal of
nutritional biochemistry, 64, 110-120.
157.
Munagala, R., Aqil, F., Jeyabalan, J., & Gupta, R. C. (2016). Bovine milk-derived
exosomes for drug delivery. Cancer letters, 371(1), 48-61.
158.
Gebhardt, S., Lemar, L., Haytowitz, D., Pehrsson, P., Nickle, M., Showell, B., ... &
Holden, J. (2008). USDA national nutrient database for standard reference, release 21.
United States Department of AgricultureAgricultural Research Service.
159.
Csak, T., Ganz, M., Pespisa, J., Kodys, K., Dolganiuc, A., & Szabo, G. (2011).
Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release
danger signals to stimulate immune cells. Hepatology, 54(1), 133-144.

66
160.
Nguyen, M. A., Favelyukis, S., Nguyen, A. K., Reichart, D., Scott, P. A., Jenn, A.,
... & Olefsky, J. M. (2007). A subpopulation of macrophages infiltrates hypertrophic adipose
tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent
pathways. Journal of Biological Chemistry, 282(48), 35279-35292.
161.
Reynolds, C. M., McGillicuddy, F. C., Harford, K. A., Finucane, O. M., Mills, K. H.,
& Roche, H. M. (2012). Dietary saturated fatty acids prime the NLRP 3 inflammasome via
TLR 4 in dendritic cells—implications for diet‐induced insulin resistance. Molecular nutrition
& food research, 56(8), 1212-1222.
162.
Shi, H., Kokoeva, M. V., Inouye, K., Tzameli, I., Yin, H., & Flier, J. S. (2006). TLR4
links innate immunity and fatty acid–induced insulin resistance. The Journal of clinical
investigation, 116(11), 3015-3025.
163.
Wen, H., Gris, D., Lei, Y., Jha, S., Zhang, L., Huang, M. T. H., ... & Ting, J. P.
(2011). Fatty acid–induced NLRP3-ASC inflammasome activation interferes with insulin
signaling. Nature immunology, 12(5), 408.
164.
Gianfrancesco, M. A., Dehairs, J., L'homme, L., Herinckx, G., Esser, N., Jansen,
O., ... & Piette, J. (2019). Saturated fatty acids induce NLRP3 activation in human
macrophages through K+ efflux resulting from phospholipid saturation and Na, K-ATPase
disruption. Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids.
165.
Li, X., Wang, L., Nguyen, T., & Zhang, Y. (2016). Enhanced endothelial
permeability by free fatty acid due to lysosomal cathepsin B-mediated activation of Nlrp3
inflammasome. The FASEB Journal, 30(1_supplement), 1198-2.
166.
Finucane, O. M., Lyons, C. L., Murphy, A. M., Reynolds, C. M., Klinger, R., Healy,
N. P., ... & O’reilly, M. E. (2015). Monounsaturated fatty acid–enriched high-fat diets
impede adipose NLRP3 inflammasome–mediated IL-1β secretion and insulin resistance
despite obesity. Diabetes, 64(6), 2116-2128.
167.
Boden, G., & Shulman, G. I. (2002). Free fatty acids in obesity and type 2 diabetes:
defining their role in the development of insulin resistance and β‐cell dysfunction. European
journal of clinical investigation, 32, 14-23.
168.
Luo, X., Yang, Y., Shen, T., Tang, X., Xiao, Y., Zou, T., ... & Ling, W. (2012).
Docosahexaenoic acid ameliorates palmitate-induced lipid accumulation and inflammation
through repressing NLRC4 inflammasome activation in HepG2 cells. Nutrition &
metabolism, 9(1), 34.
169.
Robinson, D. R., Urakaze, M., Huang, R., Taki, H., Sugiyama, E., Knoell, C. T., ...
& Auron, P. E. (1996). Dietary marine lipids suppress continuous expression of interleukin1β gene transcription. Lipids, 31(1), S23-S31.
170.
Lin, C., Chao, H., Li, Z., Xu, X., Liu, Y., Bao, Z., ... & Liu, N. (2017). Omega-3 fatty
acids regulate NLRP3 inflammasome activation and prevent behavior deficits after
traumatic brain injury. Experimental neurology, 290, 115-122.
171.
Lee, K. R., Midgette, Y., & Shah, R. (2018). Fish Oil Derived Omega 3 Fatty Acids
Suppress Adipose NLRP3 Inflammasome Signaling in Human Obesity. Journal of the
Endocrine Society, 3(3), 504-515.
172.
Shen, L., Yang, Y., Ou, T., Key, C. C. C., Tong, S. H., Sequeira, R. C., ... &
Shewale, S. V. (2017). Dietary PUFAs attenuate NLRP3 inflammasome activation via
enhancing macrophage autophagy. Journal of lipid research, 58(9), 1808-1821.
173.
Cipollina, C., Di Vincenzo, S., Piparo, D. L., & Pace, E. (2017). Late Breaking
Abstract-17-oxo-DHA inhibits the NLRP3 inflammasome downstream of mitochondrial
ROS and ERK pathway.
174.
Tsai, P. Y., Ka, S. M., Chang, J. M., Chen, H. C., Shui, H. A., Li, C. Y., ... & Chen,
A. (2011). Epigallocatechin-3-gallate prevents lupus nephritis development in mice via
enhancing the Nrf2 antioxidant pathway and inhibiting NLRP3 inflammasome activation.
Free Radical Biology and Medicine, 51(3), 744-754.

67
175.
Yin, H., Guo, Q., Li, X., Tang, T., Li, C., Wang, H., ... & Yi, F. (2018). Curcumin
suppresses IL-1β secretion and prevents inflammation through inhibition of the NLRP3
inflammasome. The Journal of Immunology, 200(8), 2835-2846.
176.
Wang, X., Zhang, Z. F., Zheng, G. H., Wang, A. M., Sun, C. H., Qin, S. P., ... &
Zheng, Y. L. (2017). The inhibitory effects of purple sweet potato color on hepatic
inflammation is associated with restoration of NAD+ levels and attenuation of NLRP3
inflammasome activation in high-fat-diet-treated mice. Molecules, 22(8), 1315.
177.
Chuang, C. C., & McIntosh, M. K. (2011). Potential mechanisms by which
polyphenol-rich grapes prevent obesity-mediated inflammation and metabolic diseases.
Annual review of nutrition, 31, 155-176.
178.
Terra, X., Montagut, G., Bustos, M., Llopiz, N., Ardèvol, A., Bladé, C., ... & Blay,
M. (2009). Grape-seed procyanidins prevent low-grade inflammation by modulating
cytokine expression in rats fed a high-fat diet. The Journal of nutritional biochemistry, 20(3),
210-218.
179.
Dou, W., Zhang, J., Ren, G., Ding, L., Sun, A., Deng, C., ... & Wang, Z. (2014).
Mangiferin attenuates the symptoms of dextran sulfate sodium-induced colitis in mice via
NF-κB and MAPK signaling inactivation. International immunopharmacology, 23(1), 170178.
180.
Song, J., Li, J., Hou, F., Wang, X., & Liu, B. (2015). Mangiferin inhibits endoplasmic
reticulum stress-associated thioredoxin-interacting protein/NLRP3 inflammasome
activation with regulation of AMPK in endothelial cells. Metabolism, 64(3), 428-437.
181.
Pan, C. W., Pan, Z. Z., Hu, J. J., Chen, W. L., Zhou, G. Y., Lin, W., ... & Xu, C. L.
(2016). Mangiferin alleviates lipopolysaccharide and D-galactosamine-induced acute liver
injury by activating the Nrf2 pathway and inhibiting NLRP3 inflammasome activation.
European journal of pharmacology, 770, 85-91.
182.
Fan, K., Ma, J., Xiao, W., Chen, J., Wu, J., Ren, J., ... & Yu, B. (2017). Mangiferin
attenuates blast-induced traumatic brain injury via inhibiting NLRP3 inflammasome.
Chemico-biological interactions, 271, 15-23.
183.
Qu, S., Wang, W., Li, D., Li, S., Zhang, L., Fu, Y., & Zhang, N. (2017). Mangiferin
inhibits mastitis induced by LPS via suppressing NF-ĸB and NLRP3 signaling pathways.
International immunopharmacology, 43, 85-90.
184.
Vaszilesin, C. G., Dan, M. L., Duca, D. A., & Labosel, M. A. (2017). Resveratrol as
corrosion inhibitor for metals in wine and food industries. In 22nd International Symposium
on Analytical and Environmental Problems.
185.
Chang, Y. P., Ka, S. M., Hsu, W. H., Chen, A., Chao, L. K., Lin, C. C., ... & Chiu,
Y. C. (2015). Resveratrol inhibits NLRP3 inflammasome activation by preserving
mitochondrial integrity and augmenting autophagy. Journal of cellular physiology, 230(7),
1567-1579.
186.
He, Q., Li, Z., Wang, Y., Hou, Y., Li, L., & Zhao, J. (2017). Resveratrol alleviates
cerebral ischemia/reperfusion injury in rats by inhibiting NLRP3 inflammasome activation
through Sirt1-dependent autophagy induction. International immunopharmacology, 50,
208-215.
187.
Yu, C., He, Q., Zheng, J., Li, L. Y., Hou, Y. H., & Song, F. Z. (2017). Sulforaphane
improves outcomes and slows cerebral ischemic/reperfusion injury via inhibition of NLRP3
inflammasome activation in rats. International immunopharmacology, 45, 74-78.
188.
Yang, G., Yeon, S. H., Lee, H. E., Kang, H. C., Cho, Y. Y., Lee, H. S., & Lee, J. Y.
(2018). Suppression of NLRP3 inflammasome by oral treatment with sulforaphane
alleviates acute gouty inflammation. Rheumatology, 57(4), 727-736.
189.
Hsieh, C. Y., Li, L. H., Rao, Y. K., Ju, T. C., Nai, Y. S., Chen, Y. W., & Hua, K. F.
(2019). Mechanistic insight into the attenuation of gouty inflammation by Taiwanese green
propolis via inhibition of the NLRP3 inflammasome. Journal of cellular physiology, 234(4),
4081-4094.

68
190.
Wang, L., Yu, Z., Wei, C., Zhang, L., Song, H., Chen, B., & Yang, Q. (2017). Huaier
aqueous extract protects against dextran sulfate sodium-induced experimental colitis in
mice by inhibiting NLRP3 inflammasome activation. Oncotarget, 8(20), 32937.
191.
Lavi, I., Levinson, D., Peri, I., Nimri, L., Hadar, Y., & Schwartz, B. (2010). Orally
administered glucans from the edible mushroom Pleurotus pulmonarius reduce acute
inflammation in dextran sulfate sodium-induced experimental colitis. British journal of
nutrition, 103(3), 393-402.
192.
Wu, S. J., Lu, T. M., Lai, M. N., & Ng, L. T. (2013). Immunomodulatory activities of
medicinal mushroom Grifola frondosa extract and its bioactive constituent. The American
journal of Chinese medicine, 41(01), 131-144.
193.
Han, J. M., Lee, E. K., Gong, S. Y., Sohng, J. K., Kang, Y. J., & Jung, H. J. (2019).
Sparassis crispa exerts anti-inflammatory activity via suppression of TLR-mediated NF-κB
and MAPK signaling pathways in LPS-induced RAW264. 7 macrophage cells. Journal of
ethnopharmacology, 231, 10-18.
194.
Dudhgaonkar, S., Thyagarajan, A., & Sliva, D. (2009). Suppression of the
inflammatory response by triterpenes isolated from the mushroom Ganoderma lucidum.
International immunopharmacology, 9(11), 1272-1280.
195.
Jedinak, A., Dudhgaonkar, S., Wu, Q. L., Simon, J., & Sliva, D. (2011). Antiinflammatory activity of edible oyster mushroom is mediated through the inhibition of NFκB and AP-1 signaling. Nutrition journal, 10(1), 52.
196.
Chang, H. H., Hsieh, K. Y., Yeh, C. H., Tu, Y. P., & Sheu, F. (2010). Oral
administration of an Enoki mushroom protein FVE activates innate and adaptive immunity
and induces anti-tumor activity against murine hepatocellular carcinoma. International
immunopharmacology, 10(2), 239-246.
197.
Ye, M., Liu, J. K., Lu, Z. X., Zhao, Y., Liu, S. F., Li, L. L., ... & Cao, Y. (2005).
Grifolin, a potential antitumor natural product from the mushroom Albatrellus confluens,
inhibits tumor cell growth by inducing apoptosis in vitro. FEBS letters, 579(16), 3437-3443.
198.
Youn, M. J., Kim, J. K., Park, S. Y., Kim, Y., Kim, S. J., Lee, J. S., ... & Kim, K. Y.
(2008). Chaga mushroom (Inonotus obliquus) induces G0/G1 arrest and apoptosis in
human hepatoma HepG2 cells. World Journal of Gastroenterology: WJG, 14(4), 511.
199.
Koyama, Y., Katsuno, Y., Miyoshi, N., Hayakawa, S., Mita, T., Muto, H., ... &
Isemura, M. (2002). Apoptosis induction by lectin isolated from the mushroom Boletopsis
leucomelas in U937 cells. Bioscience, biotechnology, and biochemistry, 66(4), 784-789.
200.
Wang, F. F., Shi, C., Yang, Y., Fang, Y., Sheng, L., & Li, N. (2018). Medicinal
mushroom Phellinus igniarius induced cell apoptosis in gastric cancer SGC-7901 through
a mitochondria-dependent pathway. Biomedicine & Pharmacotherapy, 102, 18-25.
201.
Wang, Y., Xu, G., Tang, X., & Chen, H. (2017). Polysaccharide lentinan extracted
from the stipe of Lentinus edodes mushroom exerts anticancer activities through the
transcriptional regulation of cell cycle progression and metastatic markers in human colon
cancer cells. The FASEB Journal, 31(1_supplement), lb391-lb391.
202.
Grube, B. J., Eng, E. T., Kao, Y. C., Kwon, A., & Chen, S. (2001). White button
mushroom phytochemicals inhibit aromatase activity and breast cancer cell proliferation.
The Journal of nutrition, 131(12), 3288-3293.
203.
Guo, J., Zhu, T., Collins, L., Xiao, Z. X. J., Kim, S. H., & Chen, C. Y. (2007).
Modulation of lung cancer growth arrest and apoptosis by Phellinus Linteus. Molecular
Carcinogenesis: Published in cooperation with the University of Texas MD Anderson
Cancer Center, 46(2), 144-154.
204.
Hetland, G., Johnson, E., Lyberg, T., Bernardshaw, S., Tryggestad, A. M. A., &
Grinde, B. (2008). Effects of the medicinal mushroom Agaricus blazei Murill on immunity,
infection and cancer. Scandinavian journal of immunology, 68(4), 363-370.
205.
Cheung, L. M., & Cheung, P. C. (2005). Mushroom extracts with antioxidant activity
against lipid peroxidation. Food Chemistry, 89(3), 403-409.

69
206.
Turkoglu, A., Duru, M. E., Mercan, N., Kivrak, I., & Gezer, K. (2007). Antioxidant
and antimicrobial activities of Laetiporus sulphureus (Bull.) Murrill. Food Chemistry, 101(1),
267-273.
207.
Wu, D., Pae, M., Ren, Z., Guo, Z., Smith, D., & Meydani, S. N. (2007). Dietary
supplementation with white button mushroom enhances natural killer cell activity in
C57BL/6 mice. The Journal of nutrition, 137(6), 1472-1477.
208.
Dai, X., Stanilka, J. M., Rowe, C. A., Esteves, E. A., Nieves Jr, C., Spaiser, S. J.,
... & Percival, S. S. (2015). Consuming Lentinula edodes (Shiitake) mushrooms daily
improves human immunity: A randomized dietary intervention in healthy young adults.
Journal of the American College of Nutrition, 34(6), 478-487.
209.
Dalloul, R. A., Lillehoj, H. S., Lee, J. S., Lee, S. H., & Chung, K. S. (2006).
Immunopotentiating effect of a Fomitella fraxinea-derived lectin on chicken immunity and
resistance to coccidiosis. Poultry science, 85(3), 446-451.
210.
Jayakumar, T., Ramesh, E., & Geraldine, P. (2006). Antioxidant activity of the
oyster mushroom, Pleurotus ostreatus, on CCl4-induced liver injury in rats. Food and
Chemical Toxicology, 44(12), 1989-1996.
211.
Shah, S. R., Ukaegbu, C. I., Hamid, H. A., & Alara, O. R. (2018). Evaluation of
antioxidant and antibacterial activities of the stems of Flammulina velutipes and
Hypsizygus tessellatus (white and brown var.) extracted with different solvents. Journal of
Food Measurement and Characterization, 12, 1947-1961.
212.
Dinarello, C. A. (1998). Interleukin‐1β, Interleukin‐18, and the Interleukin‐1β
Converting Enzyme a. Annals of the New York Academy of Sciences, 856(1), 1-11.
213.
Hong, P., Li, F. X., Gu, R. N., Fang, Y. Y., Lai, L. Y., Wang, Y. W., ... & Zhang, H.
F. (2018). Inhibition of NLRP3 inflammasome ameliorates cerebral ischemia-reperfusion
injury in diabetic mice. Neural plasticity, 2018.
214.
Yin, J., Zhao, F., Chojnacki, J. E., Fulp, J., Klein, W. L., Zhang, S., & Zhu, X. (2018).
NLRP3 inflammasome inhibitor ameliorates amyloid pathology in a mouse model of
Alzheimer’s disease. Molecular neurobiology, 55(3), 1977-1987.
215.
Jansen, T. L., Klück, V., Janssen, M., Comarniceanu, A., Efdé, M., Scribner, C. L.,
... & Joosten, L. A. (2019). P160 The first phase 2A proof-of-concept study of a selective
NLRP3 inflammasome inhibitor, dapansutrile™(OLT1177™), in acute gout.
216.
Spreafico, R., Ricciardi‐Castagnoli, P., & Mortellaro, A. (2010). The controversial
relationship between NLRP3, alum, danger signals and the next‐generation adjuvants.
European journal of immunology, 40(3), 638-642.
217.
Jo, E. K., Kim, J. K., Shin, D. M., & Sasakawa, C. (2016). Molecular mechanisms
regulating NLRP3 inflammasome activation. Cellular & molecular immunology, 13(2), 148.
218.
He, Y., Zeng, M. Y., Yang, D., Motro, B., & Núñez, G. (2016). NEK7 is an essential
mediator of NLRP3 activation downstream of potassium efflux. Nature, 530(7590), 354.
219.
Leiferman, A., Shu, J., Grove, R., Cui, J., Adamec, J., & Zempleni, J. (2018). A diet
defined by its content of bovine milk exosomes and their RNA cargos has moderate effects
on gene expression, amino acid profiles and grip strength in skeletal muscle in C57BL/6
mice. The Journal of nutritional biochemistry, 59, 123-128.
220.
Baier, S. R., Nguyen, C., Xie, F., Wood, J. R., & Zempleni, J. (2014). MicroRNAs
are absorbed in biologically meaningful amounts from nutritionally relevant doses of cow
milk and affect gene expression in peripheral blood mononuclear cells, HEK-293 kidney
cell cultures, and mouse livers. The Journal of nutrition, 144(10), 1495-1500.
221.
Wasser, S. P., & Weis, A. L. (1999). Therapeutic effects of substances occurring
in higher Basidiomycetes mushrooms: a modern perspective. Critical Reviews™ in
Immunology, 19(1).
222.
Huang, T. T., Ojcius, D. M., Young, J. D., Wu, Y. H., Ko, Y. F., Wong, T. Y., ... &
Lai, H. C. (2012). The anti-tumorigenic mushroom Agaricus blazei Murill enhances IL-1β

70
production and activates the NLRP3 inflammasome in human macrophages. PLoS One,
7(7), e41383.
223.
Yang, Y., Inatsuka, C., Disis, M. L., & Lu, H. (2013). Protein-bound polysaccharide
induces IL-1β via NLRP3 inflammasome activation.
224.
Liu, W., Ji, J., Chen, Z. Z., & Yan, H. (2015). Lentinan plays synergistic effects in
paclitaxel-induced A549 cell apoptosis via activating ROS-TXNIP-NLRP3 signal. Journal
of Cellular and Molecular Medicine, 19, 1949-1955.
225.
Li, X., Jin, Q., Zhang, Y., Wu, Y. L., Jin, C. M., Cui, B. W., ... & Yang, H. X. (2018).
Inhibition of P2X7R–NLRP3 Inflammasome Activation by Pleurotus citrinopileatus: A
Possible Protective Role in Alcoholic Hepatosteatosis. Journal of agricultural and food
chemistry, 66(50), 13183-13190.
226.
Tian, T., Zhu, Y. L., Zhou, Y. Y., Liang, G. F., Wang, Y. Y., Hu, F. H., & Xiao, Z. D.
(2014). Exosome uptake through clathrin-mediated endocytosis and macropinocytosis and
mediating miR-21 delivery. Journal of Biological Chemistry, 289(32), 22258-22267.
227.
Ahn, H., Jeon, E., Kim, J. C., Kang, S. G., Yoon, S. I., Ko, H. J., ... & Lee, G. S.
(2017). Lentinan from shiitake selectively attenuates AIM2 and non-canonical
inflammasome activation while inducing pro-inflammatory cytokine production. Scientific
reports, 7(1), 1314.
228.
Zempleni, J., Aguilar-Lozano, A., Sadri, M., Sukreet, S., Manca, S., Wu, D., ... &
Mutai, E. (2016). Biological activities of extracellular vesicles and their cargos from bovine
and human milk in humans and implications for infants. The Journal of nutrition, 147(1), 310.
229.
Izumi, H., Tsuda, M., Sato, Y., Kosaka, N., Ochiya, T., Iwamoto, H., ... & Takeda,
Y. (2015). Bovine milk exosomes contain microRNA and mRNA and are taken up by
human macrophages. Journal of dairy science, 98(5), 2920-2933.
230.
Wyss-Coray, T., & Mucke, L. (2002). Inflammation in neurodegenerative disease—
a double-edged sword. Neuron, 35(3), 419-432.
231.
Davis, B. K., Wen, H., & Ting, J. P. Y. (2011). The inflammasome NLRs in
immunity, inflammation, and associated diseases. Annual review of immunology, 29, 707735.
232.
Braddock, M., & Quinn, A. (2004). Targeting IL-1 in inflammatory disease: new
opportunities for therapeutic intervention. Nature reviews Drug discovery, 3(4), 330.
233.
Yan, Y., Jiang, W., Liu, L., Wang, X., Ding, C., Tian, Z., & Zhou, R. (2015).
Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome.
Cell, 160(1-2), 62-73.
234.
Hernandez-Cuellar, E., Tsuchiya, K., Hara, H., Fang, R., Sakai, S., Kawamura, I.,
... & Mitsuyama, M. (2012). Cutting edge: nitric oxide inhibits the NLRP3 inflammasome.
The Journal of Immunology, 189(11), 5113-5117.
235.
Mao, K., Chen, S., Chen, M., Ma, Y., Wang, Y., Huang, B., ... & Li, J. (2013). Nitric
oxide suppresses NLRP3 inflammasome activation and protects against LPS-induced
septic shock. Cell research, 23(2), 201.
236.
Ward, R., Li, W., Abdul, Y., Jackson, L., Dong, G., Jamil, S., ... & Ergul, A. (2019).
NLRP3 inflammasome inhibition with MCC950 improves diabetes-mediated cognitive
impairment and vasoneuronal remodeling after ischemia. Pharmacological research, 142,
237-250.
237.
Jiang, W., Li, M., He, F., & Zhu, L. (2019). Inhibition of NLRP3 inflammasome
attenuates spinal cord injury‐induced lung injury in mice. Journal of cellular physiology,
234(5), 6012-6022.
238.
Wang, L., Schmidt, S., Larsen, P. P., Meyer, J. H., Roush, W. R., Latz, E., ... &
Krohne, T. U. (2019). Efficacy of novel selective NLRP3 inhibitors in human and murine
retinal pigment epithelial cells. Journal of Molecular Medicine, 1-10.

71
239.
Zhou, X., Wu, Y., Ye, L., Wang, Y., Zhang, K., Wang, L., ... & Chen, Y. (2019).
Aspirin alleviates endothelial gap junction dysfunction through inhibition of NLRP3
inflammasome activation in LPS-induced vascular injury. Acta Pharmaceutica Sinica B.
240.
Han, X., Sun, S., Sun, Y., Song, Q., Zhu, J., Song, N., ... & Lu, M. (2019). Small
molecule-driven NLRP3 inflammation inhibition via interplay between ubiquitination and
autophagy: implications for Parkinson disease. Autophagy, 1-22.
241.
Chen, C., Wei, Y. Z., He, X. M., Li, D. D., Wang, G., Li, J. J., & Zhang, F. (2019).
Naringenin produces neuroprotection against LPS-induced dopamine neurotoxicity via the
inhibition of microglial NLRP3 inflammasome activation. Frontiers in Immunology, 10, 936.
242.
Lee, E. H., Shin, J. H., Kim, S. S., Lee, H., Yang, S. R., & Seo, S. R. (2019). Laurus
nobilis leaf extract controls inflammation by suppressing NLRP3 inflammasome activation.
Journal of cellular physiology, 234(5), 6854-6864.
243.
Zhang, M., Viennois, E., Prasad, M., Zhang, Y., Wang, L., Zhang, Z., ... & Merlin,
D. (2016). Edible ginger-derived nanoparticles: A novel therapeutic approach for the
prevention and treatment of inflammatory bowel disease and colitis-associated cancer.
Biomaterials, 101, 321-340.
244.
Zhuang, X., Deng, Z. B., Mu, J., Zhang, L., Yan, J., Miller, D., ... & Zhang, H. G.
(2015). Ginger-derived nanoparticles protect against alcohol-induced liver damage.
Journal of extracellular vesicles, 4(1), 28713.
245.
Zhou, F., Paz, H. A., Sadri, M., Fernando, S. C., & Zempleni, J. (2017). A diet
defined by its content of bovine milk exosomes alters the composition of the intestinal
microbiome in C57BL/6 mice. The FASEB Journal, 31(1_supplement), 965-24.
246.
Li, B., Hock, A., Wu, R. Y., Minich, A., Botts, S. R., Lee, C., ... & Zani, A. (2019).
Bovine milk-derived exosomes enhance goblet cell activity and prevent the development
of experimental necrotizing enterocolitis. PloS one, 14(1), e0211431.
247.
Chen, X., Zhou, Y., & Yu, J. (2019). Exosome-like Nanoparticles from Ginger
Rhizomes Inhibited NLRP3 Inflammasome Activation. Molecular pharmaceutics.
248.
Teng, Y., Ren, Y., Sayed, M., Hu, X., Lei, C., Kumar, A., ... & Sundaram, K. (2018).
Plant-derived exosomal MicroRNAs shape the gut microbiota. Cell host & microbe, 24(5),

